Inflammation and Alzheimer's disease.
PDF (272K)
+19 authors
Journal: 2000/September - Neurobiology of Aging
ISSN: 0197-4580
PUBMED: 10858586
Abstract:
Inflammation clearly occurs in pathologically vulnerable regions of the Alzheimer's disease (AD) brain, and it does so with the full complexity of local peripheral inflammatory responses. In the periphery, degenerating tissue and the deposition of highly insoluble abnormal materials are classical stimulants of inflammation. Likewise, in the AD brain damaged neurons and neurites and highly insoluble amyloid beta peptide deposits and neurofibrillary tangles provide obvious stimuli for inflammation. Because these stimuli are discrete, microlocalized, and present from early preclinical to terminal stages of AD, local upregulation of complement, cytokines, acute phase reactants, and other inflammatory mediators is also discrete, microlocalized, and chronic. Cumulated over many years, direct and bystander damage from AD inflammatory mechanisms is likely to significantly exacerbate the very pathogenic processes that gave rise to it. Thus, animal models and clinical studies, although still in their infancy, strongly suggest that AD inflammation significantly contributes to AD pathogenesis. By better understanding AD inflammatory and immunoregulatory processes, it should be possible to develop anti-inflammatory approaches that may not cure AD but will likely help slow the progression or delay the onset of this devastating disorder.
Open in
PUBMED | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(1K+)
References
(606)
Diseases
(1)
Conditions
(1)
Organisms
(1)
Anatomy
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Neurobiol Aging 21(3): 383-421
PMID: 10858586

Inflammation and Alzheimer’s disease

+28 authors
Sun Health Research Institute, 10515 West Santa Fe Drive, P.O. Box 1278, Sun City, AZ, USA 85372
Corresponding author: Tel.: +1-623-876-5328; fax: +1-623-876-5461. gro.htlaehnus.liam@sregorj (J. Rogers)
Copyright notice

Abstract

Inflammation clearly occurs in pathologically vulnerable regions of the Alzheimer’s disease (AD) brain, and it does so with the full complexity of local peripheral inflammatory responses. In the periphery, degenerating tissue and the deposition of highly insoluble abnormal materials are classical stimulants of inflammation. Likewise, in the AD brain damaged neurons and neurites and highly insoluble amyloid β peptide deposits and neurofibrillary tangles provide obvious stimuli for inflammation. Because these stimuli are discrete, microlocalized, and present from early preclinical to terminal stages of AD, local upregulation of complement, cytokines, acute phase reactants, and other inflammatory mediators is also discrete, microlocalized, and chronic. Cumulated over many years, direct and bystander damage from AD inflammatory mechanisms is likely to significantly exacerbate the very pathogenic processes that gave rise to it. Thus, animal models and clinical studies, although still in their infancy, strongly suggest that AD inflammation significantly contributes to AD pathogenesis. By better understanding AD inflammatory and immunoregulatory processes, it should be possible to develop anti-inflammatory approaches that may not cure AD but will likely help slow the progression or delay the onset of this devastating disorder.

Keywords: Alzheimer’s disease, Inflammation, Nervous system, Neuroinflammation, Complement, Cytokine, Chemokine, Acute phase protein, Microglia, Astrocyte, Neuron
Abstract

References

  • 1. Anonymous The Canadian Study of Health and Aging: risk factors for Alzheimer’s disease in Canada. Neurology. 1994;44:2073–80.[PubMed][Google Scholar]
  • 2. Abraham CR, Selkoe DJ, Potter HImmunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer’s disease. Cell. 1988;52:487–501.[PubMed][Google Scholar]
  • 3. Adams DO, Hamilton TA The Macrophage. Oxford: IRL; 1992. Molecular basis of macrophage activation. [PubMed][Google Scholar]
  • 4. Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJLocalization and cell association of C1q in Alzheimer’s disease brain. Exp Neurol. 1996;138:22–32.[PubMed][Google Scholar]
  • 5. Aguado F, Ballabriga J, Pozas E, Ferrer ITrkA immunoreactivity in reactive astrocytes in human neurodegenerative diseases and colchicine-treated rats. Acta Neuropathol (Berlin) 1998;96:495–501.[PubMed][Google Scholar]
  • 6. Aisen PS, Davis KLInflammatory mechanisms in Alzheimer’s disease: implications for therapy. Am J Psychiatry. 1994;151:1105–13.[PubMed][Google Scholar]
  • 7. Aisen PS, Pasinetti GMGlucocorticoids in Alzheimer’s disease. The story so far Drugs Aging. 1998;12:1–6.[PubMed][Google Scholar]
  • 8. Akassoglou K, Probert L, Kontogeorgos G, Kollias GAstrocyte-specific but not neuron-specific transmembrane TNF triggers inflammation and degeneration in the central nervous system of transgenic mice. J Immunol. 1997;158:438–45.[PubMed][Google Scholar]
  • 9. Akira S, Taga T, Kishimoto TIL-6 in biology and medicine. Adv Immunol. 1993;54:1–78.[PubMed][Google Scholar]
  • 10. Akiyama H, Ikeda K, Kondo H, McGeer PLThrombin accumulation in brains of patients with Alzheimer’s disease. Neurosci Lett. 1992;146:152–4.[PubMed][Google Scholar]
  • 11. Akiyama H, Kawamata T, Dedhar S, McGeer PLImmunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue. J Neuroimmunol. 1991;32:19–28.[PubMed][Google Scholar]
  • 12. Akiyama H, Kawamata T, Yamada T, Tooyama I, Ishii T, McGeer PLExpression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological disorders. Acta Neuropathol (Berlin) 1993;85:628–34.[PubMed][Google Scholar]
  • 13. Akiyama H, Kondo H, Ikeda K, Arai T, Kato M, McGleer PLImmunohistochemical detection of coagulation factor XIIIa in postmortem human brain tissue. Neurosci Lett. 1995;202:29–32.[PubMed][Google Scholar]
  • 14. Akiyama H, McGeer PLBrain microglia constitutively express beta-2 integrins. J Neuroimmunol. 1990;30:81–93.[PubMed][Google Scholar]
  • 15. Akwa Y, Hassett DE, Eloranta ML, et al Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J Immunol. 1998;161:5016–26.[PubMed][Google Scholar]
  • 16. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman ADo nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology. 1995;45:1441–5.[PubMed][Google Scholar]
  • 17. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke JWThe myeloperoxidase system of human phagocytes generates nepsilon-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest. 1999;104:103–13.[Google Scholar]
  • 18. Ando Y, Brannstrom T, Uchida K, et al Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J Neurol Sci. 1998;156:172–6.[PubMed][Google Scholar]
  • 19. Antel JP, Becher B, Owens TImmunotherapy for multiple sclerosis: from theory to practice [comment] Nat Med. 1996;2:1074–5.[PubMed][Google Scholar]
  • 20. Araki W, Kitaguchi N, Tokushima Y, et al Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. Biochem Biophys Res Commun. 1991;181:265–71.[PubMed][Google Scholar]
  • 21. Ard MD, Cole GM, Wei J, Mehrle AP, Fratkin JDScavenging of Alzheimer’s Amyloid β-protein by microglia in culture. J Neurosci Res. 1996;43:190–202.[PubMed][Google Scholar]
  • 22. Asensio VC, Campell ILChemokines in the CNS: plurifunctional mediators in diverse states. Trends Neurosci. 1999;22:504–12.[PubMed][Google Scholar]
  • 23. Ata AK, Funa K, Olsson YExpression of various TGF-beta isoforms and type I receptor in necrotizing human brain lesions. Acta Neuropathol (Berlin) 1997;93:326–33.[PubMed][Google Scholar]
  • 24. Bagasra O, Michaels FH, Zheng YM, et al Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA. 1995;92:12041–5.[Google Scholar]
  • 25. Bales KR, Du Y, Dodel RC, Yan GM, Hamilton–Byrd E, Paul SMThe NF-kappaB/Rel family of proteins mediates Abeta-induced neurotoxicity and glial activation. Mol Brain Res. 1998;57:63–72.[PubMed][Google Scholar]
  • 26. Banati RB, Gehrmann J, Kreutzberg GWGlial beta-amyloid precursor protein: expression in the dentate gyrus after entorhinal cortex lesion. Neuroreport. 1994;5:1359–61.[PubMed][Google Scholar]
  • 27. Banati RB, Gehrmann J, Schubert P, Kreutzberg GWCytotoxicity of microglia. Glia. 1993;7:111–8.[PubMed][Google Scholar]
  • 28. Barger SW, Harmon ADMicroglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature. 1997;388:878–81.[PubMed][Google Scholar]
  • 29. Barger SW, Horster D, Furukawa K, Goodman Y, Krieglstein J, Mattson MPTNFs alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc Natl Acad Sci USA. 1995;92:9328–32.[Google Scholar]
  • 30. Barnum SR, Jones JLTransforming growth factor-beta 1 inhibits inflammatory cytokine-induced C3 gene expression in astrocytes. J Immunol. 1994;152:765–73.[PubMed][Google Scholar]
  • 31. Barnum SR, Jones JL, Muller–Ladner U, Samimi A, Campbell ILChronic complement C3 gene expression in the CNS of transgenic mice with astrocyte-targeted IL-6 expression. Glia. 1996;18:107–17.[PubMed][Google Scholar]
  • 32. Bauer J, Ganter U, Abel J, et al. Effects of IL-1 and IL-6 on metallothionein and amyloid precursor protein expression in human neuroblastoma cells. Evidence that IL-6 possibly acts via a receptor different from the 80-kDa IL-6 receptor. J Neuroimmunol. 1993;45:163–73.[PubMed]
  • 33. Bauer J, Konig G, Strauss S, Jonas U, Ganter U, Weidemann A, Monning U, Masters CL, Volk B, Berger MIn-vitro matured human macrophages express Alzheimer’s beta A4-amyloid precursor protein indicating synthesis in microglial cells. FEBS Lett. 1991;282:335–40.[PubMed][Google Scholar]
  • 34. Bauer J, Strauss S, Schreiter–Gasser U, et al IL-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer’s disease cortices. FEBS Lett. 1991;285:111–4.[PubMed][Google Scholar]
  • 35. Bauer MK, Lieb K, Schulze–Osthoff K, et al Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem. 1997;243:726–31.[PubMed][Google Scholar]
  • 36. Bazan JF, Bacon KB, Hardiman G, et al A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640–4.[PubMed][Google Scholar]
  • 37. Beard CM, Kokman E, Kurland LTRheumatoid arthritis and susceptibility to Alzheimer’s disease. Lancet. 1991;337:1426.[PubMed][Google Scholar]
  • 38. Beffert U, Arguin C, Poirier JThe polymorphism in exon 3 of the low density lipoprotein receptor-related protein gene is weakly associated with Alzheimer’s disease. Neurosci Lett. 1999;259:29–32.[PubMed][Google Scholar]
  • 39. Behl C. Alzheimer’s disease, and oxidative stress. Implications for novel therapeutic approaches. Prog Neurobiol. 1999;57:301–23.[PubMed]
  • 40. Betmouni S, Perry VH, Gordon JLEvidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience. 1996;74:1–5.[PubMed][Google Scholar]
  • 41. Bitting L, Naidu A, Cordell B, Murphy GMJ. β-amyloid peptide secretion by a microglial cell line is induced by b-amyloid (25–35) and lipopolysaccharide. J Biol Chem. 1996;271:16084–9.[PubMed]
  • 42. Blacker D, Wilcox MA, Laird NM, et al Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet. 1998;19:357–60.[PubMed][Google Scholar]
  • 43. Blin J, Ivanoiu A, Coppens A, et al Cholinergic neurotransmission has different effects on cerebral glucose consumption and blood flow in young normals, aged normals, and Alzheimer’s disease patients. Neuroimage. 1997;6:335–43.[PubMed][Google Scholar]
  • 44. Blom MA, van Twillert MG, de Vries SC, Engels F, Finch CE, Veerhuis R, Eikelenboom PNSAIDS inhibit the IL-1 beta-induced IL-6 release from human postmortem astrocytes: the involvement of prostaglandin E2. Brain Res. 1997;777:210–8.[PubMed][Google Scholar]
  • 45. Bluthe RM, Dantzer R, Kelley KWEffects of IL-1 receptor antagonist on the behavioral effects of lipopolysaccharide in rat. Brain Res. 1992;573:318–20.[PubMed][Google Scholar]
  • 46. Bobinski M, de Leon MJ, Convit A, et al MRI of entorhinal cortex in mild Alzheimer’s disease. Lancet. 1999;353:38–40.[PubMed][Google Scholar]
  • 47. Border WA, Noble NATGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 1997;51:1388–96.[PubMed][Google Scholar]
  • 48. Borth W. α2-macroglobulin, a multifunctional binding protein with targeting characteristics. FASEB J. 1992;6:3345–53.[PubMed]
  • 49. Botchkina GI, Meistrell ME, Botchkina IL, Tracey KJExpression of TNF and TNF receptors (p55 and p75) in the rat brain after focal cerebral ischemia. Mol Med. 1997;3:765–81.[Google Scholar]
  • 50. Bottner M, Unsicker K, Suter–Crazzolara CExpression of TGF-beta type II receptor mRNA in the CNS. Neuroreport. 1996;7:2903–7.[PubMed][Google Scholar]
  • 51. Bradt BM, Kolb WP, Cooper NRComplement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J Exp Med. 1998;188:431–8.[Google Scholar]
  • 52. Brattsand R, Linden MCytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10 (Suppl 2):81–90.[PubMed][Google Scholar]
  • 53. Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CBDistribution and characterization of TNF-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol. 1993;337:543–67.[PubMed][Google Scholar]
  • 54. Breitner JC, Gau BA, Welsh KA, et al Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology. 1994;44:227–32.[PubMed][Google Scholar]
  • 55. Breitner JC, Welsh KA, Helms MJ, et al Delayed onset of Alzheimer’s disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs. Neurobiol Aging. 1995;16:523–30.[PubMed][Google Scholar]
  • 56. Broe GA, Henderson AS, Creasey H, et al A case-control study of Alzheimer’s disease in Australia. Neurology. 1990;40:1698–1707.[PubMed][Google Scholar]
  • 57. Brown P Immunologic mechanisms in Neurologic and Psychiatric Disease. New York: Raven Press; 1990. The phantagasmagoric immunology of transmissible spongiform encephalopathy. [PubMed][Google Scholar]
  • 58. Bruccoleri A, Pennypacker KR, Harry GJEffect of dexamethasone on elevated cytokine mRNA levels in chemical-induced hippocampal injury. J Neurosci Res. 1999;57:916–26.[PubMed][Google Scholar]
  • 59. Bruce–Keller AJ, Geddes JW, Knapp PE, et al Anti-death properties of TNF against metabolic poisoning: mitochondrial stabilization by MnSOD. J Neuroimmunol. 1999;93:53–71.[PubMed][Google Scholar]
  • 60. Bruce AJ, Boling W, Kindy MS, et al Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med. 1996;2:788–94.[PubMed][Google Scholar]
  • 61. Buttini M, Mir A, Appel K, et al Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram. Br J Pharmacol. 1997;122:1483–9.[Google Scholar]
  • 62. Buxbaum JD, Liu KN, Luo Y, et al Evidence that TNF alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem. 1998;273:27765–7.[PubMed][Google Scholar]
  • 63. Buxbaum JD, Oishi M, Chen HI, et al Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc Natl Acad Sci USA. 1992;89:10075–8.[Google Scholar]
  • 64. Cacabelos R, Alvarez XA, Fernandez–Novoa L, et al Brain IL-1 beta in Alzheimer’s disease and vascular dementia. Methods Find Exp Clin Pharmacol. 1994;16:141–51.[PubMed][Google Scholar]
  • 65. Cameron HA, Gould EAdult neurogenesis is regulated by adrenal steroids in the dentate gyrus. Neuroscience. 1994;61:203–9.[PubMed][Google Scholar]
  • 66. Campbell ILTransgenic mice and cytokine actions in the brain: bridging the gap between structural and functional neuropathology. Brain Res Rev. 1998;26:327–36.[PubMed][Google Scholar]
  • 67. Campbell IL, Abraham CR, Masliah E, et al Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci USA. 1993;90:10061–5.[Google Scholar]
  • 68. Cardinaux J-R, Allaman I, Magistretti PJPro-inflammatory cytokines induce the transcription factors C/EBP-beta and C/EBP-delta in astrocytes. Glia. 2000;29:91–7.[PubMed][Google Scholar]
  • 69. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson BAn endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–70.[Google Scholar]
  • 70. Castano A, Lawson LJ, Fearn S, Perry VHActivation and proliferation of murine microglia are insensitive to glucocorticoids in Wallerian degeneration. Eur J Neurosci. 1996;8:581–8.[PubMed][Google Scholar]
  • 71. Castano EM, Prelli F, Wisniewski T, et al Fibrillogenesis in Alzheimer’s disease of amyloid β peptides and apolipoprotein E. Biochem J. 1995;306:599–604.[Google Scholar]
  • 72. Chao CC, Ala TA, Hu S, et al Serum cytokine levels in patients with Alzheimer’s disease. Clin Diagn Lab Immunol. 1994;1:433–6.[Google Scholar]
  • 73. Chao CC, Hu S, Frey WH, Ala TA, Tourtellotte WW, Peterson PKTransforming growth factor beta in Alzheimer’s disease. Clin Diagn Lab Immunol. 1994;1:109–10.[Google Scholar]
  • 74. Chao CC, Hu S, Molitor TW, Shaskan EG, Peterson PKActivated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol. 1992;149:2736–41.[PubMed][Google Scholar]
  • 75. Chao CC, Hu S, Sheng WS, Bu D, Bukrinsky MI, Peterson PKCytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia. 1996;16:276–84.[PubMed][Google Scholar]
  • 76. Chao CC, Hu S, Tsang M, et al. Effects of transforming growth factor-beta on murine astrocyte glutamine synthetase activity. Implications in neuronal injury. J Clin Invest. 1992;90:1786–93.
  • 77. Chen J, Marsh T, Zhang JS, Graham SHExpression of cyclooxygenase 2 in rat brain following kainate treatment. Neuroreport. 1995;6:245–8.[PubMed][Google Scholar]
  • 78. Chen S, Frederickson RC, Brunden KRNeuroglial-mediated immunoinflammatory responses in Alzheimer’s disease: complement activation and therapeutic approaches. Neurobiol Aging. 1996;17:781–7.[PubMed][Google Scholar]
  • 79. Chiang CS, Powell HC, Gold LH, Samimi A, Campbell ILMacrophage/microglial-mediated primary demyelination and motor disease induced by the central nervous system production of IL-3 in transgenic mice. J Clin Invest. 1996;97:1512–24.[Google Scholar]
  • 80. Chong YEffect of a carboxy-terminal fragment of the Alzheimer’s amyloid precursor protein on expression of proinflammatory cytokines in rat glial cells. Life Sci. 1997;61:2323–33.[PubMed][Google Scholar]
  • 81. Chun JT, Wang L, Pasinetti GM, Finch CE, Zlokovic BVGlycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp Neurol. 1999;157:194–201.[PubMed][Google Scholar]
  • 82. Collaco–Morales Y, Aspey B, Harrison M, de Belleroche JCyclooxygenase-2 messenger RNA induction in focal cerebral ischemia. J Cereb Blood Flow Metab. 1996;16:1366–72.[PubMed][Google Scholar]
  • 83. Colton CA, Gilbert DLProduction of superoxide anions by a CNS macrophage, the microglia. FEBS Lett. 1987;223:284–8.[PubMed][Google Scholar]
  • 84. Combs CK, Johnson DE, Cannady SB, Lehman TM, Landreth GEIdentification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of beta-amyloid and prion proteins. J Neurosci. 1999;19:928–39.[Google Scholar]
  • 85. Combs CK, Johnson DE, Karlo C, Cannady SB, Landreth GEInflammatory mechanisms in Alzheimer’s disease: inhibition of β-amyloid stimulated proinflammatory responses and neurotoxicity by PPARγ agonists. J Neurosci. 2000;20:558–67.[Google Scholar]
  • 86. Constam DB, Philipp J, Malipiero UV, ten Dijke P, Schachner M, Fontana ADifferential expression of transforming growth factor-beta 1, -beta 2, and -beta 3 by glioblastoma cells, astrocytes, and microglia. J Immunol. 1992;148:1404–10.[PubMed][Google Scholar]
  • 87. Coria F, Castano E, Prelli F, et al Isolation and characterization of amyloid P component from Alzheimer’s disease and other types of cerebral amyloidosis. Lab Invest. 1988;58:454–8.[PubMed][Google Scholar]
  • 88. Coria F, Moreno A, Rubio I, Garcia MA, Morato E, Mayor FJThe cellular pathology associated with Alzheimer beta-amyloid deposits in nondemented aged individuals. Neuropathol Appl Neurobiol. 1993;19:261–8.[PubMed][Google Scholar]
  • 89. Cotman CW, Tenner AJ. β-amyloid converts an acute phase injury response to chronic injury response. Neurobiol Aging. 1996;17:723–31.[PubMed]
  • 90. Crawford F, Town T, Freeman M, et al The alpha-2 macroglobulin gene is not associated with Alzheimer’s disease in a case-control sample. Neurosci Lett. 1999;270:133–6.[PubMed][Google Scholar]
  • 91. Crowl RM, Stoller TJ, Conroy RR, Stoner CRInduction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991;266:2647–51.[PubMed][Google Scholar]
  • 92. Cuenod CA, Denys A, Michot JL, et al. Amygdala atrophy in Alzheimer’s disease. An in vivo magnetic resonance imaging study. Arch Neurol. 1993;50:941–5.[PubMed]
  • 93. Curtis–Prior P, Vere D, Fray PTherapeutic value of Ginkgo biloba in reducing symptoms of decline in mental function. J Pharm Pharmacol. 1999;51:535–41.[PubMed][Google Scholar]
  • 94. D’Souza SD, Bonetti B, Balasingam V, et al Multiple sclerosis: fas signaling in oligodendrocyte cell death. J Exp Med. 1996;184:2361–70.[Google Scholar]
  • 95. da Cunha A, Jefferson JA, Jackson RW, Vitkovic LGlial cell-specific mechanisms of TGF-beta 1 induction by IL-1 in cerebral cortex. J Neuroimmunol. 1993;42:71–85.[PubMed][Google Scholar]
  • 96. Das S, Potter HExpression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1. Neuron. 1995;14:447–56.[PubMed][Google Scholar]
  • 97. Davis EJ, Foster TD, Thomas WECellular forms and functions of brain microglia. Brain Res Bull. 1994;34:73–8.[PubMed][Google Scholar]
  • 98. Davis JB, McMurray HF, Schubert DThe amyloid beta-protein of Alzheimer’s disease is chemotactic for mononuclear phagocytes. Biochem Biophys Res Commun. 1992;189:1096–1100.[PubMed][Google Scholar]
  • 99. Davoust N, Jones J, Stahel PF, Ames RS, Barnum SRReceptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia. 1999;26:201–11.[PubMed][Google Scholar]
  • 100. Dawson VL, Dawson TMNitric oxide neurotoxicity. J Chem Neuroanat. 1996;10:179–90.[PubMed][Google Scholar]
  • 101. de Leon MJ, McRae T, Rusinek H, et al Cortisol reduces hippocampal glucose metabolism in normal elderly, but not in Alzheimer’s disease. J Clin Endocrinol Metab. 1997;82:3251–9.[PubMed][Google Scholar]
  • 102. De Vos K, Goossens V, Boone E, et al The 55-kDa TNF receptor induces clustering of mitochondria through its membrane-proximal region. J Biol Chem. 1998;273:9673–80.[PubMed][Google Scholar]
  • 103. Deb S, Gottschall PEIncreased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem. 1996;66:1641–7.[PubMed][Google Scholar]
  • 104. Del Bo R, Angeretti N, Lucca E, De Simoni MG, Forloni GReciprocal control of inflammatory cytokines, IL-1 and IL-6, and beta-amyloid production in cultures. Neurosci Lett. 1995;188:70–4.[PubMed][Google Scholar]
  • 105. Della–Bianca V, Dusi S, Bianchini E, et al β amyloid activates the O2 forming NADPH oxidase in microglia, monocytes and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer’s disease. J Biol Chem. 1999;274:15493–9.[PubMed][Google Scholar]
  • 106. DeWitt DA, Perry G, Cohen M, Doller C, Silver JAstrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer’s disease. Exp Neurol. 1998;149:329–40.[PubMed][Google Scholar]
  • 107. Dickson DW, Lee SC, Mattiace LA, Yen SH, Brosnan CMicroglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer’s disease. Glia. 1993;7:75–83.[PubMed][Google Scholar]
  • 108. Donnelly RJ, Friedhoff AJ, Beer B, Blume AJ, Vitek MPIL-1 stimulates the beta-amyloid precursor protein promoter. Cell Mol Neurobiol. 1990;10:485–95.[PubMed][Google Scholar]
  • 109. Droillard MJ, Guclu J, Le Caer JP, Mathieu Y, Guern J, Lauriere CIdentification of calreticulin-like protein as one of the phosphoproteins modulated in response to oligogalacturonides in tobacco cells. Planta. 1997;202:341–8.[PubMed][Google Scholar]
  • 110. Du Y, Bales KR, Dodel RC, et al Alpha2-macroglobulin attenuates beta-amyloid peptide 1–40 fibril formation and associated neurotoxicity of cultured fetal rat cortical neurons. J Neurochem. 1998;70:1182–8.[PubMed][Google Scholar]
  • 111. Du Y, Ni B, Glinn M, et al Alpha2-macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem. 1997;69:299–305.[PubMed][Google Scholar]
  • 112. Duong T, Pommier EC, Scheibel ABImmunodetection of the amyloid P component in Alzheimer’s disease. Acta Neuropathol (Berlin) 1989;78:429–37.[PubMed][Google Scholar]
  • 113. Dzenko KA, Weltzien RB, Pachter JSSuppression of A beta-induced monocyte neurotoxicity by antiinflammatory compounds. J Neuroimmunol. 1997;80:6–12.[PubMed][Google Scholar]
  • 114. Eder JTumour necrosis factor alpha and interleukin 1 signalling: do MAPKK kinases connect it all? Trends Pharmacol Sci. 1997;18:319–22.[PubMed][Google Scholar]
  • 115. Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques. An immunoperoxidase study. Acta Neuropathol. 1982;57:239–42.[PubMed]
  • 116. Eikelenboom P, Stam FCAn immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer’s dementia. Virchows Arch B Cell Pathol. 1984;47:17–25.[PubMed][Google Scholar]
  • 117. El Khoury J, Hickman SE, Thomas CA, Cao L, Silverstein SC, Loike JDScavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. Nature. 1996;382:716–9.[PubMed][Google Scholar]
  • 118. El Khoury J, Hickman SE, Thomas CA, Loike JD, Silverstein SCMicroglia, scavenger receptors, and the pathogenesis of Alzheimer’s disease. Neurobiol Aging. 1998;19:S81–4.[PubMed][Google Scholar]
  • 119. Eriksson S, Janciauskiene S, Lannfelt LAlpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc Natl Acad Sci USA. 1995;92:2313–7.[Google Scholar]
  • 120. Espey MG, Chernyshev ON, Reinhard JFJ, Namboodiri MA, Colton CAActivated human microglia produce the excitotoxin quinolinic acid. Neuroreport. 1997;8:431–4.[PubMed][Google Scholar]
  • 121. Evans KC, Berger EP, Cho CG, Weisgraber KH, Lansbury PTJApolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc Natl Acad Sci USA. 1995;92:763–7.[Google Scholar]
  • 122. Fan FS, Shen HH, Tseng WP, Chen PM, Tsai SFMolecular cloning and characterization of a human brain-specific gene implicated in neuronal differentiation. Mol Brain Res. 1998;54:113–23.[PubMed][Google Scholar]
  • 123. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CBInvolvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by IL-1, TNF-alpha, and lipopolysaccharide. J Clin Invest. 1995;95:1669–75.[Google Scholar]
  • 124. Feuerstein GZ, Liu T, Barone FCCytokines, inflammation, and brain injury: role of TNF-alpha. Cerebrovasc Brain Metab Rev. 1994;6:341–60.[PubMed][Google Scholar]
  • 125. Fiebich BL, Hofer TJ, Lieb K, et al The non-steroidal anti-inflammatory drug tepoxalin inhibits IL-6 and alpha1-anti-chymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha. Neuropharmacology. 1999;38:1325–33.[PubMed][Google Scholar]
  • 126. Fiebich BL, Hull M, Lieb K, Gyufko K, Berger M, Bauer JProstaglandin E2 induces IL-6 synthesis in human astrocytoma cells. J Neurochem. 1997;68:704–9.[PubMed][Google Scholar]
  • 127. Fiebich BL, Lieb K, Hull M, Berger M, Bauer JEffects of NSAIDs on IL-1 beta-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport. 1996;7:1209–13.[PubMed][Google Scholar]
  • 128. Fillit H, Ding WH, Buee L, et al Elevated circulating TNF levels in Alzheimer’s disease. Neurosci Lett. 1991;129:318–20.[PubMed][Google Scholar]
  • 129. Fillit H, Leveugle BDisorders of the extracellular matrix and the pathogenesis of senile dementia of the Alzheimer’s type. Lab Invest. 1995;72:249–53.[PubMed][Google Scholar]
  • 130. Finch CE, editor. Clusterin in normal brain functions and during neurodegeneration. Austin, TX: RG Landes; 1999. [PubMed]
  • 131. Finch CE, Laping NJ, Morgan TE, Nichols NR, Pasinetti GMTGF-beta 1 is an organizer of responses to neurodegeneration. J Cell Biochem. 1993;53:314–22.[PubMed][Google Scholar]
  • 132. Fischer B, Schmoll H, Riederer P, Bauer J, Platt D, Popa–Wagner AComplement C1q and C3 mRNA expression in the frontal cortex of Alzheimer’s patients. J Mol Med. 1995;73:465–71.[PubMed][Google Scholar]
  • 133. Flanders KC, Lippa CF, Smith TW, Pollen DA, Sporn MBAltered expression of transforming growth factor-beta in Alzheimer’s disease. Neurology. 1995;45:1561–9.[PubMed][Google Scholar]
  • 134. Flanders KC, Ren RF, Lippa CFTransforming growth factor-betas in neurodegenerative disease. Prog Neurobiol. 1998;54:71–85.[PubMed][Google Scholar]
  • 135. Fletcher BS, Kujubu DA, Perrin DM, Herschman HRStructure of the mitogen-inducible TIS10 gene and demonstration that the TIS10-encoded protein is a functional prostaglandin G/H synthase. J Biol Chem. 1992;267:4338–44.[PubMed][Google Scholar]
  • 136. Forloni GNeurotoxicity of beta-amyloid and prion peptides. Curr Opin Neurol. 1996;9:492–500.[PubMed][Google Scholar]
  • 137. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti NExpression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by IL-1. Mol Brain Res. 1992;16:128–34.[PubMed][Google Scholar]
  • 138. Fraser PE, Nguyen JT, McLachlan DR, Abraham CR, Kirschner DAAlpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J Neurochem. 1993;61:298–305.[PubMed][Google Scholar]
  • 139. Frautschy SA, Cole GM, Baird APhagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am J Pathol. 1992;140:1389–99.[Google Scholar]
  • 140. Frautschy SA, Yang F, Calderon L, Cole GMRodent models of Alzheimer’s disease: rat A beta infusion approaches to amyloid deposits. Neurobiol Aging. 1996;17:311–21.[PubMed][Google Scholar]
  • 141. Frautschy SA, Yang F, Irrizarry M, et al Microglial response to amyloid plaques in APPsw transgenic mice. Am J Pathol. 1998;152:307–17.[Google Scholar]
  • 142. Frei K, Malipiero UV, Leist TP, Zinkernagel RM, Schwab ME, Fontana AOn the cellular source and function of interleukin 6 produced in the central nervous system in viral diseases. Eur J Immunol. 1989;19:689–94.[PubMed][Google Scholar]
  • 143. French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians BA case-control study of dementia of the Alzheimer type. Am J Epidemiol. 1985;121:414–21.[PubMed][Google Scholar]
  • 144. Frucht SJ, Koo EHbeta-Amyloid protein is higher in Alzheimer’s disease brains: description of a quantitative biochemical assay. J Neuropathol Exp Neurol. 1993;52:640–7.[PubMed][Google Scholar]
  • 145. Gadient RA, Otten UHIL-6—a molecule with both beneficial and destructive potentials. Prog Neurobiol. 1997;52:379–90.[PubMed][Google Scholar]
  • 146. Ganter U, Strauss S, Jonas U, et al. Alpha 2-macroglobulin synthesis in IL-6-stimulated human neuronal (SH-SY5Y neuroblastoma) cells. Potential significance for the processing of Alzheimer beta-amyloid precursor protein. FEBS Lett. 1991;282:127–31.[PubMed]
  • 147. Gary DS, Bruce–Keller AJ, Kindy MS, Mattson MPIschemic and excitotoxic brain injury is enhanced in mice lacking the p55 TNF receptor. J Cereb Blood Flow Metab. 1998;18:1283–7.[PubMed][Google Scholar]
  • 148. Gasque P, Chan P, Fontaine M, et al Identification and characterization of the complement C5a anaphylatoxin receptor on human astrocytes. J Immunol. 1995;155:4882–9.[PubMed][Google Scholar]
  • 149. Gasque P, Fontaine M, Morgan BP. Complement expression in human brain. Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J Immunol. 1995;154:4726–33.[PubMed]
  • 150. Gasque P, Ischenko A, Legoedec J, Mauger C, Schouft MT, Fontaine M. Expression of the complement classical pathway by human glioma in culture. A model for complement expression by nerve cells. J Biol Chem. 1993;268:25068–74.[PubMed]
  • 151. Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BPExpression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol. 1997;150:31–41.[Google Scholar]
  • 152. Gasque P, Tenner AJ, Morgan BPExpression of the C1q/MBL/SPA receptor involved in phagocytosis and innate immune defense on human glia. Mol Immunol. 1998;35:379.[PubMed][Google Scholar]
  • 153. Gayle D, Ilyin SE, Miele ME, Plata–Salaman CRModulation of TNF-alpha mRNA production in rat C6 glioma cells by TNF-alpha, IL-1beta, IL-6, and IFN-alpha: in vitro analysis of cytokine-cytokine interactions. Brain Res Bull. 1998;47:231–5.[PubMed][Google Scholar]
  • 154. Gehrmann J, Mies G, Bonnekoh P, Banati R, Iijima T, Kreutzberg GW, Hossmann KAMicroglial reaction in the rat cerebral cortex induced by cortical spreading depression. Brain Pathol. 1993;3:11–7.[PubMed][Google Scholar]
  • 155. Geula C, Wu CK, Saroff D, Lorenzo A, Yuan M, Yankner BAAging renders the brain vulnerable to amyloid beta-protein neurotoxicity. Nat Med. 1998;4:827–31.[PubMed][Google Scholar]
  • 156. Gewurz H, Ying SC, Jiang H, Lint TFNonimmune activation of the classical complement pathway. Behring Inst Mitt. 1993:138–47.[PubMed][Google Scholar]
  • 157. Giulian D, Baker TJ, Shih LC, Lachman LBInterleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med. 1986;164:594–604.[Google Scholar]
  • 158. Giulian D, Haverkamp LJ, Li J, et al Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain. Neurochem Int. 1995;27:119–37.[PubMed][Google Scholar]
  • 159. Giulian D, Haverkamp LJ, Yu J, et al The HHQK domain of beta-amyloid provides a structural basis for the immunopathology of Alzheimer’s disease. J Biol Chem. 1998;273:29719–26.[PubMed][Google Scholar]
  • 160. Giulian D, Haverkamp LJ, Yu JH, et al Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J Neurosci. 1996;16:6021–37.[Google Scholar]
  • 161. Giulian D, Woodward J, Young DG, Krebs JF, Lachman LBIL-1 injected into mammalian brain stimulates astrogliosis and neovascularization. J Neurosci. 1988;8:2485–90.[Google Scholar]
  • 162. Glabinski AR, Ransohoff RMChemokines and chemokine receptors in CNS pathology. J Neurovirol. 1999;5:3–12.[PubMed][Google Scholar]
  • 163. Goate AThe future of Alzheimer’s disease research: a molecular genetic perspective. Neurobiol Aging. 1994;15(Suppl 2):S161–4.[PubMed][Google Scholar]
  • 164. Goldgaber D, Harris HW, Hla T, et al Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA. 1989;86:7606–10.[Google Scholar]
  • 165. Gollin PA, Kalaria RN, Eikelenboom P, Rozemuller A, Perry GAlpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer’s disease. Neuroreport. 1992;3:201–3.[PubMed][Google Scholar]
  • 166. Gong C, Qin Z, Betz AL, Liu XH, Yang GYCellular localization of TNF alpha following focal cerebral ischemia in mice. Brain Res. 1998;801:1–8.[PubMed][Google Scholar]
  • 167. Good PF, Werner P, Hsu A, Olanow CW, Perl DPEvidence of neuronal oxidative damage in Alzheimer’s disease. Am J Pathol. 1996;149:21–8.[Google Scholar]
  • 168. Goodwin JL, Uemura E, Cunnick JEMicroglia release of nitric oxide by the synergistic action of β-amyloid and IFN-γBrain Res. 1995:207–14.[PubMed][Google Scholar]
  • 169. Graves AB, White E, Koepsell TD, et al A case-control study of Alzheimer’s disease. Ann Neurol. 1990;28:766–74.[PubMed][Google Scholar]
  • 170. Gray CW, Patel AJRegulation of beta-amyloid precursor protein isoform mRNAs by transforming growth factor-beta 1 and IL-1 beta in astrocytes. Mol Brain Res. 1993;19:251–6.[PubMed][Google Scholar]
  • 171. Greenberg CS, Birckbichler PJ, Rice RHTransglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991;5:3071–7.[PubMed][Google Scholar]
  • 172. Greenberg SMCerebral amyloid angiopathy: prospects for clinical diagnosis and treatment. Neurology. 1998;51:690–4.[PubMed][Google Scholar]
  • 173. Griffin WS, Sheng JG, Gentleman SM, Graham DI, Mrak RE, Roberts GWMicroglial IL-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett. 1994;176:133–6.[Google Scholar]
  • 174. Griffin WS, Sheng JG, Roberts GW, Mrak REIL-1 expression in different plaque types in Alzheimer’s disease: significance in plaque evolution. J Neuropathol Exp Neurol. 1995;54:276–81.[PubMed][Google Scholar]
  • 175. Griffin WS, Sheng JG, Royston MC, et al Glial-neuronal interactions in Alzheimer’s disease: the potential role of a ‘cytokine cycle’ in disease progression. Brain Pathol. 1998;8:65–72.[PubMed][Google Scholar]
  • 176. Griffin WS, Stanley LC, Ling C, et al Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:7611–5.[Google Scholar]
  • 177. Grilli M, Goffi F, Memo M, Spano PIL-1beta and glutamate activate the NF-kappaB/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures. J Biol Chem. 1996;271:15002–7.[PubMed][Google Scholar]
  • 178. Gruol DL, Nelson TEPhysiological and pathological roles of IL-6 in the central nervous system. Mol Neurobiol. 1997;15:307–39.[PubMed][Google Scholar]
  • 179. Gupta–Bansal R, Frederickson RC, Brunden KRProteoglycan-mediated inhibition of Aβ hydrolysis. J Biol Chem. 1995;270:18666–71.[PubMed][Google Scholar]
  • 180. Haga S, Aizawa T, Ishii T, Ikeda KComplement gene expression in mouse microglia and astrocytes in culture: comparisons with mouse peritoneal macrophages. Neurosci Lett. 1996;216:191–4.[PubMed][Google Scholar]
  • 181. Haga S, Akai K, Ishii T. Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody. Acta Neuropathol (Berlin) 1989;77:569–75.[PubMed]
  • 182. Haga S, Ikeda K, Sato M, Ishii TSynthetic Alzheimer amyloid beta/A4 peptides enhance production of complement C3 component by cultured microglial cells. Brain Res. 1993;601:88–94.[PubMed][Google Scholar]
  • 183. Halkier D In: Mechanisms in blood coagulation, fibrinolysis, and the complement system. Woolley P, editor. Cambridge, UK: Cambridge University Press; 1991. pp. 88–103. [PubMed][Google Scholar]
  • 184. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka HIL-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience. 1991;40:445–52.[PubMed][Google Scholar]
  • 185. Hamazaki HAmyloid P component promotes aggregation of Alzheimer’s beta amyloid peptide. Biochem Biophys Res Commun. 1995;211:349–53.[PubMed][Google Scholar]
  • 186. Hampel H, Schoen D, Schwarz MJ, et al IL-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer’s disease. Neurosci Lett. 1997;228:143–6.[PubMed][Google Scholar]
  • 187. Hampel H, Sunderland T, Kotter HU, et al Decreased soluble IL-6 receptor in cerebrospinal fluid of patients with Alzheimer’s disease. Brain Res. 1998;780:356–9.[PubMed][Google Scholar]
  • 188. Hampel H, Teipel SJ, Padberg F, et al Discriminant power of combined cerebrospinal fluid tau protein and of the soluble IL-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res. 1999;823:104–12.[PubMed][Google Scholar]
  • 189. Harris–White ME, Chu T, Balverde Z, Sigel JJ, Flanders KC, Frautschy SAEffects of transforming growth factor-beta (isoforms 1–3) on amyloid-beta deposition, inflammation, and cell targeting in organotypic hippocampal slice cultures. J Neurosci. 1998;18:10366–74.[Google Scholar]
  • 190. Harris–White ME, Teter B, Chut T, et al Effects of ApoE on Aβ deposition in murine organotypic slice cultures. Neurosci. 1998;24:2136. Abstract. [PubMed][Google Scholar]
  • 191. Hartmann A, Veldhuis JD, Deuschle M, Standhardt H, Heuser ITwenty-four hour cortisol release profiles in patients with Alzheimer’s and Parkinson’s disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging. 1997;18:285–9.[PubMed][Google Scholar]
  • 192. Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just HCalcium handling proteins in the failing human heart. Basic Res Cardiol. 1997;92:87–93.[PubMed][Google Scholar]
  • 193. Hatzinger M, Seifritz E, Hemmeter U, Holsboer–Trachsler EKortisoninduzierte wahnhafte Depression bei systemischem Lupus erythematodes [Cortisone-induced delusional depression in systemic lupus erythematosus] Psychiatr Prax. 1994;21:199–203.[PubMed][Google Scholar]
  • 194. Hatzinger M, Z’Brun A, Hemmeter U, et al Hypothalamic-pituitary-adrenal system function in patients with Alzheimer’s disease. Neurobiol Aging. 1995;16:205–9.[PubMed][Google Scholar]
  • 195. Hauss–Wegrzyniak B, Dobrzanski P, Stoehr JD, Wenk GLChronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer’s disease. Brain Res. 1998;780:294–303.[PubMed][Google Scholar]
  • 196. Hauss–Wegrzyniak B, Galons JP, Wenk GLQuantitative volumetric analysis of brain magnetic resonance imaging from rat with chronic neuroinflammation and correlation with histology. Exp Neurol. In press. [[PubMed]
  • 197. Hauss–Wegrzyniak B, Vraniak P, Wenk GLThe effects of a novel NSAID upon chronic neuroinflammation are age dependent. Neurobiol Aging. 1999;20:305–13.[PubMed][Google Scholar]
  • 198. Hauss–Wegrzyniak B, Willard LB, Del Soldato P, Pepeu G, Wenk GLPeripheral administration of novel anti-inflammatories can attenuate the effects of chronic inflammation within the CNS. Brain Res. 1999;815:36–43.[PubMed][Google Scholar]
  • 199. Hawkey CJCox-2 inhibitors. Lancet. 1999;353:307–14.[PubMed][Google Scholar]
  • 200. Hedrick JA, Saylor V, Figueroa D, et al Lymphotactin is produced by NK cells and attracts both NK cells and T cells in vivo. J Immunol. 1997;158:1533–40.[PubMed][Google Scholar]
  • 201. Heine UI, Munoz EF, Flanders KC, et al Role of transforming growth factor-b in the development of the mouse embryo. J Cell Biol. 1987;105:2861–76.[Google Scholar]
  • 202. Heinrich PC, Horn F, Graeve L, et al IL-6 and related cytokines: effect on the acute phase reaction. Z Ernahrungswiss. 1998;37:43–9.[PubMed][Google Scholar]
  • 203. Hensley K, Maidt ML, Yu Z, Sang H, Markesbery WR, Floyd RAElectrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation. J Neurosci. 1998;18:8126–32.[Google Scholar]
  • 204. Hesselgesser J, Horuk RChemokine and chemokine receptor expression in the central nervous system. J Neurov. 1999;5:13–26.[PubMed][Google Scholar]
  • 205. Heyman A, Wilkinson WE, Stafford JA, Helms MJ, Sigmon AH, Weinberg TAlzheimer’s disease: a study of epidemiological aspects. Ann Neurol. 1984;15:335–41.[PubMed][Google Scholar]
  • 206. Heyser CJ, Masliah E, Samimi A, Campbell IL, Gold LHProgressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice overexpressing interleukin 6 in the brain. Proc Natl Acad Sci. 1997;94:1500–5.[Google Scholar]
  • 207. Hibi M, Murakami M, Saito M, Hirano T, Taga T, Kishimoto TMolecular cloning and expression of an IL-6 signal transducer, gp130. Cell. 1990;63:1149–57.[PubMed][Google Scholar]
  • 208. Hibi M, Nakajima K, Hirano TIL-6 cytokine family and signal transduction:a model of the cytokine system. J Mol Med. 1996;74:1–12.[PubMed][Google Scholar]
  • 209. Hickey WF, Kimura HGraft-vs.-host disease elicits expression of class I and class II histocompatibility antigens and the presence of scattered T lymphocytes in rat central nervous system. Proc Natl Acad Sci USA. 1987;84:2082–6.[Google Scholar]
  • 210. Hickey WF, Kimura HPerivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 1988;239:290–2.[PubMed][Google Scholar]
  • 211. Hirano T, Nakajima K, Hibi MSignaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8:241–52.[PubMed][Google Scholar]
  • 212. Hirst WD, Young KA, Newton R, Allport VC, Marriott DR, Wilkin GPExpression of COX-2 by normal and reactive astrocytes in the adult rat central nervous system. Mol Cell Neurosci. 1999;13:57–68.[PubMed][Google Scholar]
  • 213. Ho L, Osaka H, Aisen PS, Pasinetti GMInduction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J Neuroimmunol. 1998;89:142–9.[PubMed][Google Scholar]
  • 214. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GMRegional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer’s disease. J Neurosci Res. 1999;57:295–303.[PubMed][Google Scholar]
  • 215. Hoff SF, Scheff SW, Cotman CW. Lesion-induced synaptogenesis in the dentate gyrus of aged rats: II. Demonstration of an impaired degeneration clearing response. J Comp Neurol. 1982;205:253–9.[PubMed]
  • 216. Hollenbach E, Ackermann S, Hyman BT, Rebeck GWConfirmation of an association between a polymorphism in exon 3 of the low-density lipoprotein receptor-related protein gene and Alzheimer’s disease. Neurology. 1998;50:1905–7.[PubMed][Google Scholar]
  • 217. Holtzman DM, Bales KR, Wu S, et al Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer’s disease. J Clin Invest. 1999;103:15–21.[Google Scholar]
  • 218. Horuk R, Martin AW, Wang Z, et al Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol. 1997;158:2882–90.[PubMed][Google Scholar]
  • 219. Hsu H, Shu HB, Pan MG, Goeddel DVTRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299–308.[PubMed][Google Scholar]
  • 220. Hughes SR, Khorkova O, Goyal S, et al Alpha2-macroglobulin associates with beta-amyloid peptide and prevents fibril formation. Proc Natl Acad Sci USA. 1998;95:3275–80.[Google Scholar]
  • 221. Hugo F, Hamdoch T, Mathey D, Schafer H, Bhakdi SQuantitative measurement of SC5b-9 and C5b-9(m) in infarcted areas of human myocardium. Clin Exp Immunol. 1990;81:132–6.[Google Scholar]
  • 222. Hull M, Berger M, Volk B, Bauer JOccurrence of IL-6 in cortical plaques of Alzheimer’s disease patients may precede transformation of diffuse into neuritic plaques. Ann NY Acad Sci. 1996;777:205–12.[PubMed][Google Scholar]
  • 223. Hull M, Fiebich BL, Schumann G, Lieb K, Bauer JAnti-inflammatory substances—a new therapeutic option in Alzheimer’s disease. Drug Discovery Today. 1999;4:275–82.[PubMed][Google Scholar]
  • 224. Hunot S, Boissiere F, Faucheux B, et al Nitric oxide synthase and neuronal vulnerability in Parkinson’s Disease. Neurosci. 1996;72:355–63.[PubMed][Google Scholar]
  • 225. Hurley SD, Walter SA, Semple–Rowland SL, Streit WJCytokine transcripts expressed by microglia in vitro are not expressed by ameboid microglia of the developing rat central nervous system. Glia. 1999;25:304–9.[PubMed][Google Scholar]
  • 226. Hyman BT, Marzloff K, Arriagada PVThe lack of accumulation of senile plaques or amyloid burden n Alzheimer’s disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol. 1993;52:594–600.[PubMed][Google Scholar]
  • 227. Ignotz RA, Massague JTransforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261:4337–45.[PubMed][Google Scholar]
  • 228. Ikeda K, Kinoshita M, Tagaya N, et al Coadministration of IL-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease. Brain Res. 1996;726:91–7.[PubMed][Google Scholar]
  • 229. Imai T, Hieshima K, Haskell C, et al Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521–30.[PubMed][Google Scholar]
  • 230. Imamura T, Ishii K, Sasaki M, et al Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer’s disease: a comparative study using positron emission tomography. Neurosci Lett. 1997;235:49–52.[PubMed][Google Scholar]
  • 231. In’t Veldt V, Launer LJ, Hoes AW, et al. NSAIDs and incident Alzheimer’s disease. The Rotterdam Study. Neurobiol Aging. 1998;19:607–11.[PubMed]
  • 232. Ip NY, Nye SH, Boulton TG, et al CNTF and LIF act on neuronal cells via shared signaling pathways that involve the IL-6 signal transducing receptor component gp130. Cell. 1992;69:1121–32.[PubMed][Google Scholar]
  • 233. Ishii T, Haga SImmuno-electron-microscopic localization of complements in amyloid fibrils of senile plaques. Acta Neuropathol. 1984;63:296–300.[PubMed][Google Scholar]
  • 234. Ishizuka K, Kimura T, Igata–yi R, Katsuragi S, Takamatsu J, Miyakawa TIdentification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin Neurosci. 1997;51:135–8.[PubMed][Google Scholar]
  • 235. Itagaki S, Akiyama H, Saito H, McGeer PLUltrastuctural localization of complment membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer’s disease. Brain Res. 1994;645:78–84.[PubMed][Google Scholar]
  • 236. Itagaki S, McGeer PL, Akiyama H, Zhu S, Selkoe DRelationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24:173–82.[PubMed][Google Scholar]
  • 237. Iwamoto N, Nishiyama E, Ohwada J, Arai HDemonstration of CRP immunoreactivity in brains of Alzheimer’s disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett. 1994;177:23–6.[PubMed][Google Scholar]
  • 238. Jack CRJ, Petersen RC, O’Brien PC, Tangalos EGMR-based hippocampal volumetry in the diagnosis of Alzheimer’s disease. Neurology. 1992;42:183–8.[PubMed][Google Scholar]
  • 239. Janabi N, Hau I, Tardieu MNegative feedback between prostaglandin and alpha- and beta-chemokine synthesis in human microglial cells and astrocytes. J Immunol. 1999;162:1701–6.[PubMed][Google Scholar]
  • 240. Janciauskiene S, Garcia DF, Carlemalm E, Dahlback B, Eriksson SInhibition of Alzheimer beta-peptide fibril formation by serum amyloid P component. J Biol Chem. 1995;270:26041–4.[PubMed][Google Scholar]
  • 241. Jenkinson ML, Bliss MR, Brain AT, Scott DLRheumatoid arthritis and senile dementia of the Alzheimer’s type. Br J Rheumatol. 1989;28:86–8.[PubMed][Google Scholar]
  • 242. Jiang C, Ting AT, Seed BPPARgamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 1998;391:82–6.[PubMed][Google Scholar]
  • 243. Jiang H, Burdick D, Glabe CG, Cotman CW, Tenner AJ. β-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q a chain. Journal of Immunology. 1994;152:5050–9.[PubMed]
  • 244. Johns TG, Bernard CCBinding of complement component C1q to myelin oligodendrocyte glycoprotein:a novel mechanism for regulating CNS inflammation. Mol Immunol. 1997;34:33–8.[PubMed][Google Scholar]
  • 245. Johnson SA, Lampert–Etchells M, Pasinetti GM, Rozovsky I, Finch CEComplement mRNA in the mammalian brain: responses to Alzheimer’s disease and experimental brain lesioning. Neurobiol Aging. 1992;13:641–8.[PubMed][Google Scholar]
  • 246. Johnson SA, Young–Chan CS, Laping NJ, Finch CEPerforant path transection induces complement C9 deposition in hippocampus. Exp Neurol. 1996;138:198–205.[PubMed][Google Scholar]
  • 247. Kalaria RN, Golde T, Kroon SN, Perry GSerine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer’s disease. Am J Pathol. 1993;143:886–93.[Google Scholar]
  • 248. Kalaria RN, Kroon SNComplement inhibitor C4-binding protein in amyloid deposits containing serum amyloid P in Alzheimer’s disease. Biochem Biophys Res Comm. 1992;186:461–6.[PubMed][Google Scholar]
  • 249. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, Kaltschmidt CTranscription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:2642–7.[Google Scholar]
  • 250. Kamboh MI, Sanghera DK, Ferrell RE, DeKosky STAPOE*4-associated Alzheimer’s disease risk is modified by alpha 1- antichymotrypsin polymorphism [published erratum appears in Nat Genet 1995 Sep;11:104] Nat Genet. 1995;10:486–8.[PubMed][Google Scholar]
  • 251. Kang DE, Saitoh T, Chen X, et al Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer’s disease. Neurology. 1997;49:56–61.[PubMed][Google Scholar]
  • 252. Karpus WJ, Lukacs NW, McRae BL, Streiter RM, Kunkel SL, Miller SDAn important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol. 1995;155:5003–10.[PubMed][Google Scholar]
  • 253. Kaur C, Wu CH, Wen CY, Ling EAThe effects of subcutaneous injections of glucocorticoids on amoeboid microglia in postnatal rats. Arch Histol Cytol. 1994;57:449–59.[PubMed][Google Scholar]
  • 254. Kawamata T, Tooyama I, Yamada T, Walker DG, McGeer PLLactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am J Pathol. 1993;142:1574–85.[Google Scholar]
  • 255. Keller JN, Kindy MS, Holtsberg FW, et al Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction. J Neurosci. 1998;18:687–97.[Google Scholar]
  • 256. Kelley KA, Ho L, Winger D, et al Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol. 1999;155:995–1004.[Google Scholar]
  • 257. Kelner GS, Kennedy J, Bacon KB, et al Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994;266:1395–9.[PubMed][Google Scholar]
  • 258. Kesslak JP, Nalcioglu O, Cotman CWQuantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. Neurology. 1991;41:51–4.[PubMed][Google Scholar]
  • 259. Killiany RJ, Moss MB, Albert MS, Sandor T, Tieman J, Jolesz FTemporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer’s disease. Arch Neurol. 1993;50:949–54.[PubMed][Google Scholar]
  • 260. Kishimoto T, Akira S, Narazaki M, Taga TIL-6 family of cytokines and gp130. Blood. 1995;86:1243–54.[PubMed][Google Scholar]
  • 261. Kisilevsky RProteoglycans, glycosaminoglycans, amyloid-enhancing factor, and amyloid deposition. J Intern Med. 1992;232:515–6.[PubMed][Google Scholar]
  • 262. Kisilevsky RProteoglycans and other basement membrane proteins in amyloidoses. Mol Neurobiol. 1994;9:23–4.[PubMed][Google Scholar]
  • 263. Kitamura Y, Shimohama S, Koike H, et al Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains. Biochem Biophys Res Commun. 1999;254:582–6.[PubMed][Google Scholar]
  • 264. Klegeris A, McGeer PL. β-amyloid protein enhances macrophage production of oxygen free radicals and glutamate. J Neurosci Res. 1997;49:229–35.[PubMed]
  • 265. Klegeris A, Walker DG, McGeer PLActivation of macrophages by Alzheimer β amyloid peptide. Biochem Biophys Res Commun. 1994;199:984–91.[PubMed][Google Scholar]
  • 266. Klegeris A, Walker DG, McGeer PLInteraction of Alzheimer beta-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of TNF-alpha. Brain Res. 1997;747:114–21.[PubMed][Google Scholar]
  • 267. Kligman D, Marshak DRPurification and characterization of a neurite extension factor from bovine brain. Proc Natl Acad Sci USA. 1985;82:7136–9.[Google Scholar]
  • 268. Knuckey NW, Finch P, Palm DE, et al Differential neuronal and astrocytic expression of transforming growth factor beta isoforms in rat hippocampus following transient forebrain ischemia. Mol Brain Res. 1996;40:1–14.[PubMed][Google Scholar]
  • 269. Komori T, Shibata N, Kobayashi M, Sasaki S, Iwata MInducible nitric oxide synthase (iNOS)-like immunoreactivity in argyrophilic, tau-positive astrocytes in progressive supranuclear palsy. Acta Neuropathol (Berlin) 1998;95:338–44.[PubMed][Google Scholar]
  • 270. Kopec KK, Carroll RTAlzheimer’s beta-amyloid peptide 1–42 induces a phagocytic response in murine microglia. J Neurochem. 1998;71:2123–31.[PubMed][Google Scholar]
  • 271. Kounnas MZ, Moir RD, Rebeck GW, et al LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell. 1995;82:331–40.[PubMed][Google Scholar]
  • 272. Krieglstein K, Rufer M, Suter–Crazzolara C, Unsicker KNeural functions of the transforming growth factors beta. Int J Dev Neurosci. 1995;13:301–15.[PubMed][Google Scholar]
  • 273. Kuby J Immunology. 2. New York: WH Freeman; 1994. p. 402. [PubMed][Google Scholar]
  • 274. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HRTIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homolog. J Biol Chem. 1991;266:12866–72.[PubMed][Google Scholar]
  • 275. Kushima Y, Hama T, Hatanaka HIL-6 as a neurotrophic factor for promoting the survival of cultured catecholaminergic neurons in a chemically defined medium from fetal and postnatal rat midbrains. Neurosci Res. 1992;13:267–80.[PubMed][Google Scholar]
  • 276. Kushima Y, Hatanaka HIL-6 and leukemia inhibitory factor promote the survival of acetylcholinesterase-positive neurons in culture from embryonic rat spinal cord. Neurosci Lett. 1992;143:110–4.[PubMed][Google Scholar]
  • 277. Lacy M, Jones J, Whittemore SR, Haviland DL, Wetsel RA, Barnum SRExpression of the receptors for the C5a anaphylatoxin, IL-8 and FMLP by human astrocytes and microglia. J Neuroimmunol. 1995;61:71–8.[PubMed][Google Scholar]
  • 278. LaDu MJ, Gilligan SM, Lukens JR, et al Nascent astrocyte particles differ from lipoproteins in CSF. J Neurochem. 1998;70:2070–81.[PubMed][Google Scholar]
  • 279. Lahiri DK, Nall CPromoter activity of the gene encoding the beta-amyloid precursor protein is up-regulated by growth factors, phorbol ester, retinoic acid and IL-1. Mol Brain Res. 1995;32:233–40.[PubMed][Google Scholar]
  • 280. Lambert MP, Barlow AK, Chromy BA, et al Diffusible, nonfibrillar ligands derived from Abeta1–42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95:6448–53.[Google Scholar]
  • 281. Lampert–Etchells M, Pasinetti GM, Finch CE, Johnson SARegional localization of cells containing complement C1q and C4 mRNAs in the frontal cortex during Alzheimer’s disease. Neurodegeneration. 1993;2:111–21.[PubMed][Google Scholar]
  • 282. Lappin DF, Whaley KModulation of complement gene expression by glucocorticoids. Biochem J. 1991;280:117–23.[Google Scholar]
  • 283. Laskowitz DT, Goel S, Bennett ER, Matthew WDApolipoprotein E suppresses glial cell secretion of TNF alpha. J Neuroimmunol. 1997;76:70–4.[PubMed][Google Scholar]
  • 284. Laskowitz DT, Matthew WD, Bennett ER, et al Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production. Neuroreport. 1998;9:615–8.[PubMed][Google Scholar]
  • 285. Lavenius E, Gestblom C, Johansson I, Nanberg E, Pahlman STransfection of TRK-A into human neuroblastoma cells restores their ability to differentiate in response to nerve growth factor. Cell Growth Differ. 1995;6:727–36.[PubMed][Google Scholar]
  • 286. LeBlanc AIncreased production of 4 kDa amyloid beta peptide in serum deprived human primary neuron cultures: possible involvement of apoptosis. J Neurosci. 1995;15:7837–46.[Google Scholar]
  • 287. Lee RK, Knapp S, Wurtman RJProstaglandin E2 stimulates amyloid precursor protein gene expression: inhibition by immunosuppressants. J Neurosci. 1999;19:940–7.[Google Scholar]
  • 288. Lee SC, Dickson DW, Liu W, Brosnan CFInduction of nitric oxide synthase activity in human astrocytes by IL-1 beta and interferon-gamma. J Neuroimmunol. 1993;46:19–24.[PubMed][Google Scholar]
  • 289. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SAPeroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406–10.[PubMed][Google Scholar]
  • 290. Lehmann JM, Moore LB, Smith–Oliver TA, Wilkison WO, Willson TM, Kliewer SAAn antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARgamma) J Biol Chem. 1995;270:12953–6.[PubMed][Google Scholar]
  • 291. Lemberger T, Desvergne B, Wahli WPeroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996;12:335–63.[PubMed][Google Scholar]
  • 292. Lemercier C, Julen N, Coulpier M, et al Differential modulation by glucocorticoids of alternative complement protein secretion in cells of the monocyte/macrophage lineage. Eur J Immunol. 1992;22:909–15.[PubMed][Google Scholar]
  • 293. Leveugle B, Fillit HProteoglycans and the acute-phase response in Alzheimer’s disease brain. Mol Neurobiol. 1994;9:25–32.[PubMed][Google Scholar]
  • 294. Levi–Strauss M, Mallat MPrimary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol. 1987;139:2361–6.[PubMed][Google Scholar]
  • 295. Li G, Shen YC, Li YT, Chen CH, Zhau YW, Silverman JMA case-control study of Alzheimer’s disease in China. Neurology. 1992;42:1481–8.[PubMed][Google Scholar]
  • 296. Li Y, Liu L, Kang J, et al Neuronal-glial interactions mediated by IL-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci. 2000;20:149–55.[Google Scholar]
  • 297. Liao A, Nitsch RM, Greenberg SM, et al Genetic association of an alpha2-macroglobulin (Val1000lle) polymorphism and Alzheimer’s disease. Hum Mol Genet. 1998;7:1953–6.[PubMed][Google Scholar]
  • 298. Lim GP, Tran T, Ubeda O, et al The effect of ibuprofen on synaptic markers and open field activity in HuAAPPsw mice. Neuroscience. 1999;25:1863. Abstract. [PubMed][Google Scholar]
  • 299. Limoges J, Persidsky Y, Bock P, Gendelman HEDexamethasone therapy worsens the neuropathology of human immunodeficiency virus type 1 encephalitis in SCID mice. J Infect Dis. 1997;175:1368–81.[PubMed][Google Scholar]
  • 300. Linder E, Lehto VP, Stenman SActivation of complement by cytoskeletal intermediate filaments. Nature. 1979;278:176–8.[PubMed][Google Scholar]
  • 301. Lindholm D, Castren E, Kiefer R, Zafra F, Thoenen HTransforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation. J Cell Biol. 1992;117:395–400.[Google Scholar]
  • 302. Ling EA, Wong WCThe origin and nature of ramified and amoeboid microglia: a historical review and current concepts. Glia. 1993;7:9–18.[PubMed][Google Scholar]
  • 303. Lippa CF, Fujiwara H, Mann DM, et al Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer’s disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol. 1998;153:1365–70.[Google Scholar]
  • 304. Littman DRChemokine receptors: keys to AIDS pathogenesis? Cell. 1998;93:677–80.[PubMed][Google Scholar]
  • 305. Liu H, Bowes RC, van de Water B, Sillence C, Nagelkerke JF, Stevens JLEndoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells. J Biol Chem. 1997;272:21751–9.[PubMed][Google Scholar]
  • 306. Logan A, Berry M, Gonzalez AM, Frautschy SA, Sporn MB, Baird AEffects of transforming growth factor beta 1 on scar production in the injured central nervous system of the rat. Eur J Neurosci. 1994;6:355–63.[PubMed][Google Scholar]
  • 307. Logan A, Frautschy SA, Gonzalez AM, Sporn MB, Baird AEnhanced expression of transforming growth factor beta 1 in the rat brain after a localized cerebral injury. Brain Res. 1992;587:216–25.[Google Scholar]
  • 308. Lombardi VR, Garcia M, Cacabelos RMicroglial activation induced by factor(s) contained in sera from Alzheimer-related ApoE genotypes. J Neurosci Res. 1998;54:539–53.[PubMed][Google Scholar]
  • 309. Louis JC, Magal E, Takayama S, Varon SCNTF protection of oligodendrocytes against natural and TNF-induced death. Science. 1993;259:689–92.[PubMed][Google Scholar]
  • 310. Luber–Narod J, Rogers JImmune system associated antigens expressed by cells of the human central nervous system. Neurosci Lett. 1988;94:17–22.[PubMed][Google Scholar]
  • 311. Lucca U, Tettamanti M, Forloni G, Spagnoli ANonsteroidal anti-inflammatory drug use in Alzheimer’s disease. Biol Psychiatry. 1994;36:854–6.[PubMed][Google Scholar]
  • 312. Lue LF, Brachova L, Civin WH, Rogers JInflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration. J Neuropathol Exp Neurol. 1996;55:1083–8.[PubMed][Google Scholar]
  • 313. Lue LF, Brachova L, Shen Y, Rogers JModeling Aβ deposition in cultures of Alzheimer’s glia and hNT neurons. Neuroscience. 1999;23:533. Abstract. [PubMed][Google Scholar]
  • 314. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers JSoluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer’s disease. Am J Pathol. 1999;155:853–862.[Google Scholar]
  • 315. Lue LF, Shen Y, Yang LB, Rydel RE, Hampel H, Rogers J Constitutive and amyloid β peptide-stimulated secretion of inflammatory mediators by Alzheimer’s disease and control microglia. In: Rogers J, editor. Neuroinflammation and Alzheimer’s disease. Basel: Birkhauser Press; In press. [PubMed][Google Scholar]
  • 316. Luo J, Lang JA, Miller MWTransforming growth factor beta1 regulates the expression of cyclooxygenase in cultured cortical astrocytes and neurons. J Neurochem. 1998;71:526–34.[PubMed][Google Scholar]
  • 317. Luster ADChemokines—chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–45.[PubMed][Google Scholar]
  • 318. Ma J, Yee A, Brewer HB, Das S, Potter HAmyloid-associated protein α1-antichymotrypsin and apolipoprotein-E promote assembly of Alzheimer β-protein into filaments. Nature. 1999;372:92–4.[PubMed][Google Scholar]
  • 319. Mackenzie IRAnti-inflammatory drugs and Alzheimer type pathology in aging. Neurology. 2000;54:732–4.[PubMed][Google Scholar]
  • 320. Mackenzie IR, Hao C, Munoz DGRole of microglia in senile plaque formation. Neurobiol Aging. 1995;16:797–804.[PubMed][Google Scholar]
  • 321. Mackenzie IR, Munoz DGNonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 1998;50:986–90.[PubMed][Google Scholar]
  • 322. Majeed M, Krause KH, Clark RA, Kihlstr A, Stendahl OLocalization of intracellular Ca2+ stores in HeLa cells during infection with chlamydia trachomatis. J Cell Sci. 1998;112:35–44.[PubMed][Google Scholar]
  • 323. Malinin NL, Boldin MP, Kovalenko AV, Wallach DMAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature. 1997;385:540–4.[PubMed][Google Scholar]
  • 324. Marcheselli VL, Bazan NG. Sustained induction of prostaglandin endoperoxide synthase-2 by seizures in hippocampus. Inhibition by a platelet-activating factor antagonist. J Biol Chem. 1996;271:24794–9.[PubMed]
  • 325. Markesbery WROxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med. 1997;23:134–47.[PubMed][Google Scholar]
  • 326. Markesbery WR, Carney JMOxidative alterations in Alzheimer’s disease. Brain Pathol. 1999;9:133–46.[PubMed][Google Scholar]
  • 327. Marshak DR, Pesce SA, Stanley LC, Griffin WSIncreased S100 beta neurotrophic activity in Alzheimer’s disease temporal lobe. Neurobiol Aging. 1992;13:1–7.[PubMed][Google Scholar]
  • 328. Marz P, Cheng JG, Gadient RA, et al Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci USA. 1998;95:3251–6.[Google Scholar]
  • 329. Marz P, Gadient RA, Otten UExpression of IL-6 receptor (IL-6R) and gp130 mRNA in PC12 cells and sympathetic neurons: modulation by TNF alpha (TNF-alpha) Brain Res. 1996;706:71–9.[PubMed][Google Scholar]
  • 330. Masferrer JL, Reddy ST, Zweifel BS, et al In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther. 1994;270:1340–4.[PubMed][Google Scholar]
  • 331. Masferrer JL, Seibert KRegulation of prostaglandin synthesis by glucocorticoids. Receptor. 1994;4:25–30.[PubMed][Google Scholar]
  • 332. Masliah E, Westland CE, Rockenstein EM, et al Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience. 1997;78:135–46.[PubMed][Google Scholar]
  • 333. Massague JTGF-β signal transduction. Annu Rev Biochem. 1998;67:753–91.[PubMed][Google Scholar]
  • 334. Mastorakos G, Chrousos GP, Weber JSRecombinant IL-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690–4.[PubMed][Google Scholar]
  • 335. Mattson MPCentral role of oxyradicals in the mechanism of amyloid beta peptide cytotoxicity. Alz Dis Rev. 1997;2:1–14.[PubMed][Google Scholar]
  • 336. Mattson MP, Barger SWRoles for calcium signaling in structural plasticity and pathology in the hippocampal system. Hippocampus. 1993;3:73–87.[PubMed][Google Scholar]
  • 337. Mattson MP, Cheng B, Baldwin SA, et al Brain injury and TNFs induce calbindin D-28k in astrocytes: evidence for a cytoprotective response. J Neurosci Res. 1995;42:357–70.[PubMed][Google Scholar]
  • 338. Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel REEvidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. Neuron. 1993;10:243–54.[PubMed][Google Scholar]
  • 339. Mattson MP, Pedersen WAEffects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimer’s disease. Int J Dev Neurosci. 1998;16:737–53.[PubMed][Google Scholar]
  • 340. Mazur–Kolecka B, Frackowiak J, Wisniewski HMApolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimer’s beta-amyloid peptide in cultured vascular smooth muscle cells. Brain Res. 1995;698:217–22.[PubMed][Google Scholar]
  • 341. McCaffrey TA, Falcone DJ, Vicente D, Du B, Consigli S, Borth WProtection of transforming growth factor-beta 1 activity by heparin and fucoidan. J Cell Physiol. 1994;159:51–9.[PubMed][Google Scholar]
  • 342. McComb RD, Miller KA, Carson SDTissue factor antigen in senile plaques of Alzheimer’s disease. Am J Pathol. 1991;139:491–4.[Google Scholar]
  • 343. McDonald DR, Bamberger ME, Combs CK, Landreth GEbeta-Amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THP1 monocytes. J Neurosci. 1998;18:4451–60.[Google Scholar]
  • 344. McDonald DR, Brunden KR, Landreth GEAmyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J Neurosci. 1997;17:2284–94.[Google Scholar]
  • 345. McEwen BS, Sapolsky RMStress and cognitive function. Curr Opin Neurobiol. 1995;5:205–16.[PubMed][Google Scholar]
  • 346. McGeer PL, Akiyama H, Itagaki S, McGeer EGActivation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci Lett. 1989;107:341–6.[PubMed][Google Scholar]
  • 347. McGeer PL, Akiyama H, Itagaki S, McGeer EGImmune system response in Alzheimer’s disease. Can J Neurol Sci. 1989;16:516–27.[PubMed][Google Scholar]
  • 348. McGeer PL, Itagaki S, Boyes BE, McGeer EGReactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988;38:1285–91.[PubMed][Google Scholar]
  • 349. McGeer PL, McGeer E, Rogers J, Sibley JAnti-inflammatory drugs and Alzheimer disease. Lancet. 1990;335:1037.[PubMed][Google Scholar]
  • 350. McGeer PL, McGeer EGThe inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev. 1995;21:195–218.[PubMed][Google Scholar]
  • 351. McGeer PL, Schulzer M, McGeer EGArthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425–32.[PubMed][Google Scholar]
  • 352. McKee AC, Kowall NW, Schumacher JS, Beal MFThe neurotoxicity of amyloid beta protein in aged primates. Amyloid. 1998;5:1–9.[PubMed][Google Scholar]
  • 353. McRae A, Ling EA, Schubert P, Rudolphi KProperties of activated microglia and pharmacologic interference by propentofylline. Alzheimer Dis Assoc Disord. 1998;12:15–20.[PubMed][Google Scholar]
  • 354. Meda L, Baron P, Prat E, et al Proinflammatory profile of cytokine production by human monocytes and murine microglia stimulated with beta-amyloid[25–35] J Neuroimmunol. 1999;93:45–52.[PubMed][Google Scholar]
  • 355. Meda L, Bonaiuto C, Baron P, Otvos LJ, Rossi F, Cassatella MAPriming of monocyte respiratory burst by beta-amyloid fragment (25–35) Neurosci Lett. 1996;219:91–4.[PubMed][Google Scholar]
  • 356. Mega MS, Chen SS, Thompson PM, et al Mapping histology to metabolism: coregistration of stained whole-brain sections to pre-mortem PET in Alzheimer’s disease. Neuroimage. 1997;5:147–153.[PubMed][Google Scholar]
  • 357. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJRegional hypometabolism in Alzheimer’s disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology. 1996;47:454–61.[PubMed][Google Scholar]
  • 358. Mentlein R, Ludwig R, Martensen IProteolytic degradation of Alzheimer’s disease amyloid beta-peptide by a metalloproteinase from microglia cells. J Neurochem. 1998;70:721–6.[PubMed][Google Scholar]
  • 359. Mielke R, Heiss WDPositron emission tomography for diagnosis of Alzheimer’s disease and vascular dementia. J Neural Transm. 1998;53:237–50.[PubMed][Google Scholar]
  • 360. Miller RJ, Meucci OAIDS and the brain: is there a chemokine connection? Trends Neurosci. 1999;22:471–9.[PubMed][Google Scholar]
  • 361. Miller TP, Taylor J, Rogerson S, et al Cognitive and noncognitive symptoms in dementia patients: relationship to cortisol and dehydroepiandrosterone. Int Psychogeriatr. 1998;10:85–96.[PubMed][Google Scholar]
  • 362. Minghetti L, Nicolini A, Polazzi E, et al Down-regulation of microglial cyclo-oxygenase-2 and inducible nitric oxide synthase expression by lipocortin 1. Br J Pharmacol. 1999;126:1307–14.[Google Scholar]
  • 363. Minghetti L, Polazzi E, Nicolini A, Creminon C, Levi GInterferon-gamma and nitric oxide down-regulate lipopolysaccharide-induced prostanoid production in cultured rat microglial cells by inhibiting cyclooxygenase-2 expression. J Neurochem. 1996;66:1963–70.[PubMed][Google Scholar]
  • 364. Minghetti L, Polazzi E, Nicolini A, Levi GOpposite regulation of prostaglandin E2 synthesis by transforming growth factor-beta1 and interleukin 10 in activated microglial cultures. J Neuroimmunol. 1998;82:31–9.[PubMed][Google Scholar]
  • 365. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DEA diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.[PubMed][Google Scholar]
  • 366. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu TTNF-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. 1994;165:208–10.[PubMed][Google Scholar]
  • 367. Monning U, Sandbrink R, Banati RB, Masters CL, Beyreuther KTransforming growth factor beta mediates increase of mature transmembrane amyloid precursor protein in microglial cells. FEBS Lett. 1994;342:267–72.[PubMed][Google Scholar]
  • 368. Monsma FJJ, Shen Y, Ward RP, Hamblin MW, Sibley DRCloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320–7.[PubMed][Google Scholar]
  • 369. Montero–Julian FA, Brailly H, Sautes C, et al Characterization of soluble gp130 released by melanoma cell lines: A polyvalent antagonist of cytokines from the interleukin 6 family. Clin Cancer Res. 1997;3:1443–51.[PubMed][Google Scholar]
  • 370. Morgan TE, Nichols NR, Pasinetti GM, Finch CETGF-beta 1 mRNA increases in macrophage/microglial cells of the hippocampus in response to deafferentation and kainic acid-induced neurodegeneration. Exp Neurol. 1993;120:291–301.[PubMed][Google Scholar]
  • 371. Morgan TE, Xie Z, Goldsmith S, et al The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience. 1999;89:687–99.[PubMed][Google Scholar]
  • 372. Morioka T, Baba T, Black KL, Streit WJImmunophenotypic analysis of infiltrating leukocytes and microglia in an experimental rat glioma. Acta Neuropathol (Berlin) 1992;83:590–7.[PubMed][Google Scholar]
  • 373. Morioka T, Kalehua AN, Streit WJCharacterization of microglial reaction after middle cerebral artery occlusion in rat brain. J Comp Neurol. 1993;327:123–32.[PubMed][Google Scholar]
  • 374. Morse JK, DeKosky ST, Scheff SW. Neurotrophic effects of steroids on lesion-induced growth in the hippocampus. II. Hormone replacement. Exp Neurol. 1992;118:47–52.[PubMed]
  • 375. Mrak RE, Sheng JG, Griffin WSCorrelation of astrocytic S100 beta expression with dystrophic neurites in amyloid plaques of Alzheimer’s disease. J Neuropathol Exp Neurol. 1996;55:273–9.[Google Scholar]
  • 376. Mucke L, Abraham CR, Ruppe MD, et al Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein. J Exp Med. 1995;181:1551–6.[Google Scholar]
  • 377. Mucke L, Masliah E, Johnson WB, et al Synaptotrophic effects of human amyloid beta protein precursors in the cortex of transgenic mice. Brain Res. 1994;666:151–67.[PubMed][Google Scholar]
  • 378. Mullberg J, Dittrich E, Graeve L, et al Differential shedding of the two subunits of the IL-6 receptor. FEBS Lett. 1993;332:174–8.[PubMed][Google Scholar]
  • 379. Mullberg J, Durie FH, Otten–Evans C, et al A metalloprotease inhibitor blocks shedding of the IL-6 receptor and the p60 TNF receptor. J Immunol. 1995;155:5198–5205.[PubMed][Google Scholar]
  • 380. Mullberg J, Schooltink H, Stoyan T, et al The soluble IL-6 receptor is generated by shedding. Eur J Immunol. 1993;23:473–80.[PubMed][Google Scholar]
  • 381. Mullberg J, Schooltink H, Stoyan T, Heinrich PC, Rose–John SProtein kinase C activity is rate limiting for shedding of the IL-6 receptor. Biochem Biophys Res Commun. 1992;189:794–800.[PubMed][Google Scholar]
  • 382. Muller–Newen G, Kuster A, Hemmann U, et al Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol. 1998;161:6347–55.[PubMed][Google Scholar]
  • 383. Multhaup G, Ruppert T, Schlicksupp A, et al Reactive oxygen species and Alzheimer’s disease. Biochem Pharmacol. 1997;54:533–9.[PubMed][Google Scholar]
  • 384. Multiple Author Issue. Neurobiol Aging. 1996:17. Special Issue. [PubMed]
  • 385. Munger JS, Harpel JG, Gleizes PE, Mazzieri R, Nunes I, Rifkin DBLatent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int. 1997;51:1376–82.[PubMed][Google Scholar]
  • 386. Murphy PG, Altares M, Gauldie J, Richardson PMIL-6 promotes survival of sensory neurons. Neuroscience. 1997;23:890. Abstract. [PubMed][Google Scholar]
  • 387. Murphy PG, Borthwick LS, Johnston RS, Kuchel G, Richardson PMNature of the retrograde signal from injured nerves that induces IL-6 mRNA in neurons. J Neurosci. 1999;19:3791–3800.[Google Scholar]
  • 388. Murray RE, McGuigan F, Grant SF, Reid DM, Ralston SHPolymorphisms of the IL-6 gene are associated with bone mineral density. Bone. 1997;21:89–92.[PubMed][Google Scholar]
  • 389. Myllykangas–Luosujarvi R, Isomaki HAlzheimer’s disease and rheumatoid arthritis. Br J Rheumatol. 1994;33:501–2.[PubMed][Google Scholar]
  • 390. Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment. A prospective study. Psychoneuroendocrinology. 1996;21:25–31.[PubMed]
  • 391. Nakajima K, Shimojo M, Hamanoue M, Ishiura S, Sugita H, Kohsaka SIdentification of elastase as a secretory protease from cultured rat microglia. J Neurochem. 1992;58:1401–8.[PubMed][Google Scholar]
  • 392. Nakajima K, Tsuzaki N, Nagata K, Takemoto N, Kohsaka SProduction and secretion of plasminogen in cultured rat brain microglia. FEBS Lett. 1992;308:179–82.[PubMed][Google Scholar]
  • 393. Nakajima K, Tsuzaki N, Shimojo M, Hamanoue M, Kohsaka SMicroglia isolated from rat brain secrete a urokinase-type plasminogen activator. Brain Res. 1992;577:285–92.[PubMed][Google Scholar]
  • 394. Nakashima K, Wiese S, Yanagisawa M, et al Developmental requirement of gp130 signaling in neuronal survival and astrocyte differentiation. J Neurosci. 1999;19:5429–34.[Google Scholar]
  • 395. Nakayama M, Uchimura K, Zhu RL, et al Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA. 1998;95:10954–9.[Google Scholar]
  • 396. Narazaki M, Yasukawa K, Saito T, et al Soluble forms of the IL-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood. 1993;82:1120–6.[PubMed][Google Scholar]
  • 397. Narita M, Holtzman DM, Schwartz AL, Bu GAlpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J Neurochem. 1997;69:1904–11.[PubMed][Google Scholar]
  • 398. Nasman B, Olsson T, Fagerlund M, Eriksson S, Viitanen M, Carlstrom KBlunted adrenocorticotropin and increased adrenal steroid response to human corticotropin-releasing hormone in Alzheimer’s disease. Biol Psychiatry. 1996;39:311–8.[PubMed][Google Scholar]
  • 399. Nataf S, Stahel PF, Davoust N, Barnum SRComplement anaphylatoxin receptors on neurons: new tricks for old receptors? Trends Neurosci. 1999;22:397–402.[PubMed][Google Scholar]
  • 400. Natoli G, Costanzo A, Guido F, Moretti F, Levrero MApoptotic, non-apoptotic, and anti-apoptotic pathways of TNF signalling. Biochem Pharmacol. 1998;56:915–20.[PubMed][Google Scholar]
  • 401. Netland EE, Newton JL, Majocha RE, Tate BAIndomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging. 1998;19:201–4.[PubMed][Google Scholar]
  • 402. Nogawa S, Zhang F, Ross ME, Iadecola CCyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci. 1997;17:2746–55.[Google Scholar]
  • 403. O’Banion MKCyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol. 1999;13:45–82.[PubMed][Google Scholar]
  • 404. O’Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PDIL-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J Neurochem. 1996;66:2532–40.[PubMed][Google Scholar]
  • 405. O’Banion MK, Sadowski HB, Winn V, Young DAA serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem. 1991;266:23261–7.[PubMed][Google Scholar]
  • 406. O’Banion MK, Winn VD, Young DAcDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc Natl Acad Sci USA. 1992;89:4888–92.[Google Scholar]
  • 407. O’Hara J, Paul WEReceptors for B-cell stimulatory factor-1 expressed on cells of hematopoietic lineage. Nature. 1987;325:537–40.[PubMed][Google Scholar]
  • 408. Oka A, Takashima SInduction of cyclo-oxygenase 2 in brains of patients with Down’s syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport. 1997;8:1161–4.[PubMed][Google Scholar]
  • 409. Oken BS, Storzbach DM, Kaye JAThe efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998;55:1409–15.[PubMed][Google Scholar]
  • 410. Oliver JD, Van der Wal FJ, Bulleid NJ, High SInteraction of the thiol-dependent reductase ERp57 with nascent glycoproteins. Science. 1997;275:86–8.[PubMed][Google Scholar]
  • 411. Orzylowska O, Oderfeld–Nowak B, Zaremba M, Januszewski S, Mossakowski MProlonged and concomitant induction of astroglial immunoreactivity of IL-1beta and IL-6 in the rat hippocampus after transient global ischemia. Neurosci Lett. 1999;263:72–6.[PubMed][Google Scholar]
  • 412. Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C, Pasinetti GMExpression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience. 1999;88:1073–82.[PubMed][Google Scholar]
  • 413. Osaka H, Mukherjee P, Aisen PS, Pasinetti GMComplement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J Cell Biochem. 1999;73:303–11.[PubMed][Google Scholar]
  • 414. Padberg F, Feneberg W, Schmidt S, et al CSF and serum levels of soluble IL-6 receptors (sIL-6R and sgp130), but not of IL-6 are altered in multiple sclerosis. J Neuroimmunol. 1999;99:218–23.[PubMed][Google Scholar]
  • 415. Paonessa G, Graziani R, De Serio A, et al Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO J. 1995;14:1942–51.[Google Scholar]
  • 416. Papassotiropoulos A, Bagli M, Jessen F, et al A genetic variation of the inflammatory cytokine IL-6 delays the initial onset and reduces the risk for sporadic Alzheimer’s disease. Ann Neurol. 1999;45:666–8.[PubMed][Google Scholar]
  • 417. Paradisis PM, Campbell IL, Barnum SRElevated complement C5a receptor expression on neurons and glia in astrocyte-targeted IL-3 transgenic mice. Glia. 1998;24:338–45.[PubMed][Google Scholar]
  • 418. Paresce DM, Chung H, Maxfield FRSlow degradation of aggregates of the Alzheimer’s disease amyloid beta-protein by microglial cells. J Biol Chem. 1997;272:29390–7.[PubMed][Google Scholar]
  • 419. Pasinetti GMCyclooxygenase and inflammation in Alzheimer’s disease: experimental approaches and clinical interventions. J Neurosci Res. 1998;54:1–6.[PubMed][Google Scholar]
  • 420. Pasinetti GM, Aisen PSCyclooxygenase-2 expression is increased in frontal cortex of Alzheimer’s disease brain. Neuroscience. 1998;87:319–24.[PubMed][Google Scholar]
  • 421. Pasinetti GM, Hassler M, Stone D, Finch CEGlial gene expression during aging in rat striatum and in long-term responses to 6-OHDA lesions. Synapse. 1999;31:278–84.[PubMed][Google Scholar]
  • 422. Pasinetti GM, Johnson SA, Rozovsky I, et al Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp Neurol. 1992;118:117–25.[PubMed][Google Scholar]
  • 423. Pasinetti GM, Nichols NR, Tocco G, Morgan T, Laping N, Finch CETransforming growth factor beta 1 and fibronectin messenger RNA in rat brain: responses to injury and cell-type localization. Neuroscience. 1993;54:893–907.[PubMed][Google Scholar]
  • 424. Pasinetti GM, Tocco G, Sakhi S, et al Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol Dis. 1996;3:197–204.[PubMed][Google Scholar]
  • 425. Patthy LEvolution of blood coagulation and fibrinolysis. Blood Coagul Fibrinolysis. 1990;1:153–66.[PubMed][Google Scholar]
  • 426. Pennica D, Wood WI, Chien KRCardiotrophin-1: a multifunctional cytokine that signals via LIF receptor-gp 130 dependent pathways. Cytokine Growth Factor Rev. 1996;7:81–91.[PubMed][Google Scholar]
  • 427. Peress NS, Perillo EDifferential expression of TGF-beta 1, 2 and 3 isotypes in Alzheimer’s disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J Neuropathol Exp Neurol. 1995;54:802–11.[PubMed][Google Scholar]
  • 428. Pericak-Vance MA, Bass MP, Yamaoka LH, et al. Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. JAMA. 1997;278:1237–41.[PubMed]
  • 429. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NSMedicinal plants and Alzheimer’s disease: from ethnobotany to phytotherapy. J Pharm Pharmacol. 1999;51:527–34.[PubMed][Google Scholar]
  • 430. Perry VH, Matyszak MK, Fearn SAltered antigen expression of microglia in the aged rodent CNS. Glia. 1993;7:60–7.[PubMed][Google Scholar]
  • 431. Piani D, Spranger M, Frei K, Schaffner A, Fontana AMacrophage-induced cytotoxicity of N-methyl-D-aspartate receptor positive neurons involves excitatory amino acids rather than reactive oxygen intermediates and cytokines. Eur J Immunol. 1992;22:2429–36.[PubMed][Google Scholar]
  • 432. Plata–Salaman CRImmunoregulators in the nervous system. Neurosci Biobehav Rev. 1991;15:185–215.[PubMed][Google Scholar]
  • 433. Plata–Salaman CR. Cytokine-induced anorexia. Behavioral, cellular, and molecular mechanisms. Ann NY Acad Sci. 1998;856:160–70.[PubMed]
  • 434. Plata–Salaman CR, Ilyin SE, Gayle DBrain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol. 1998;275:R566–73.[PubMed][Google Scholar]
  • 435. Podrez EA, Schmitt D, Hoff HF, Hazen SLMyeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547–60.[Google Scholar]
  • 436. Poller W, Faber JP, Klobeck G, Olek KCloning of the human alpha 2-macroglobulin gene and detection of mutations in two functional domains: the bait region and the thiolester site. Hum Genet. 1992;88:313–9.[PubMed][Google Scholar]
  • 437. Prehn JH, Bindokas VP, Jordan J, et al Protective effect of transforming growth factor beta-1 on beta amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol. 1996;49:319–28.[PubMed][Google Scholar]
  • 438. Prieschl EE, Kulmburg PA, Baumruker TThe nomenclature of chemokines. Int Arch Allergy Immunol. 1995;107:475–83.[PubMed][Google Scholar]
  • 439. Probert L, Akassoglou K, Pasparakis M, Kontogeorgos G, Kollias GSpontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of TNF alpha. Proc Natl Acad Sci USA. 1995;92:11294–8.[Google Scholar]
  • 440. Prusiner SBThe prion diseases. Sci Am. 1995;272:48–57.[PubMed][Google Scholar]
  • 441. Qiu WQ, Ye Z, Kholodenko D, Seubert P, Selkoe DJDegradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J Biol Chem. 1997;272:6641–6.[PubMed][Google Scholar]
  • 442. Rebeck GW, Harr SD, Strickland DK, Hyman BTMultiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Ann Neurol. 1995;37:211–7.[PubMed][Google Scholar]
  • 443. Rebeck GW, Reiter JS, Strickland DK, Hyman BTApolipoprotein E in sporadic Alzheimer’s disease: allelic variation and receptor interactions. Neuron. 1993;11:575–80.[PubMed][Google Scholar]
  • 444. Reiman EM, Uecker A, Caselli RJ, et al Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer’s disease. Ann Neurol. 1998;44:288–91.[PubMed][Google Scholar]
  • 445. Reynolds WF, Rhees J, Maciejewski D, et al Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer’s disease. Exp Neurol. 1999;155:31–41.[PubMed][Google Scholar]
  • 446. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt JNonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology. 1995;45:51–5.[PubMed][Google Scholar]
  • 447. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CKThe peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79–82.[PubMed][Google Scholar]
  • 448. Ringheim GE, Szczepanik AM, Petko W, Burgher KL, Zhu SZ, Chao CCEnhancement of beta-amyloid precursor protein transcription and expression by the soluble IL-6 receptor/IL-6 complex. Mol Brain Res. 1998;55:35–44.[PubMed][Google Scholar]
  • 449. Roberts AB, Sporn MB The molecular and cellular biology of wound repair. New York: Plenum Press; 1996. Transforming growth factor-b; pp. 275–308. [PubMed][Google Scholar]
  • 450. Roberts AB, Sporn MB, Assoian RK, et al Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986;83:4167–71.[Google Scholar]
  • 451. Rodriguez M, Pavelko KD, McKinney CW, Leibowitz JLRecombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol. 1994;153:3811–21.[PubMed][Google Scholar]
  • 452. Rogers J, Cooper NR, Webster S, et al Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 1992;89:10016–20.[Google Scholar]
  • 453. Rogers J, Griffin WST. Inflammatory mechanisms of Alzheimer’s disease. In: Wood PL, editor. Neuroinflammation: mechanisms and management. Totowa, NY: Humana Press; 1998. pp. 177–93. [PubMed]
  • 454. Rogers J, Kirby LC, Hempelman SR, et al Clinical trial of indomethacin in Alzheimer’s disease. Neurology. 1993 Aug;43:1609–11.[PubMed][Google Scholar]
  • 455. Rogers J, Luber–Narod J, Styren SD, Civin WHExpression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer’s disease. Neurobiol Aging. 1988;9:339–49.[PubMed][Google Scholar]
  • 456. Rogers J, Lue LF, Yang LB, et al Complement activation by neurofibrillary tangles in Alzheimer’s disease. Neuroscience. 1998;24:1268. Abstract. [PubMed][Google Scholar]
  • 457. Rogers J, O’Barr S. Inflammatory mediators in Alzheimer’s disease. In: Tanzi RE, Wasco W, editors. Molecular approaches to Alzheimer’s Disease. Totawa, N.J: Humana Press; 1996. pp. 177–97. [PubMed]
  • 458. Rogers JT, Leiter LM, McPhee J, et al Translation of the alzheimer amyloid precursor protein mRNA is up-regulated by IL-1 through 5′-untranslated region sequences. J Biol Chem. 1999;274:6421–31.[PubMed][Google Scholar]
  • 459. Rosenblatt DE, Geula C, Mesulam MMProtease nexin 1 immunostaining in Alzheimer’s disease. Ann Neurol. 1989;26:628–34.[PubMed][Google Scholar]
  • 460. Roses AD, Saunders AMApoE, Alzheimer’s disease, and recovery from brain stress. Ann NY Acad Sci. 1997;826:200–12.[PubMed][Google Scholar]
  • 461. Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson IPropentofylline in the treatment of Alzheimer’s disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord. 1998;9:36–43.[PubMed][Google Scholar]
  • 462. Rozemuller JM, Eikelenboom P, Pals ST, Stam FCMicroglial cells around amyloid plaques in Alzheimer’s disease express leucocyte adhesion molecules of the LFA-1 family. Neurosci Lett. 1989;101:288–92.[PubMed][Google Scholar]
  • 463. Rozemuller JM, Eikelenboom P, Stam FC, Beyreuther K, Masters CLA4 protein in Alzheimer’s disease: primary and secondary cellular events in extracellular amyloid deposition. J Neuropathol Exp Neurol. 1989;48:674–91.[PubMed][Google Scholar]
  • 464. Rozovsky I, Laping NJ, Krohn K, Teter B, O’Callaghan JP, Finch CETranscriptional regulation of glial fibrillary acidic protein by corticosterone in rat astrocytes in vitro is influenced by the duration of time in culture and by astrocyte-neuron interactions. Endocrinology. 1995;136:2066–73.[PubMed][Google Scholar]
  • 465. Rozovsky I, Morgan TE, Willoughby DA, et al Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience. 1994;62:741–58.[PubMed][Google Scholar]
  • 466. Saito T, Yasukawa K, Suzuki H, et al Preparation of soluble murine IL-6 receptor and anti-murine IL-6 receptor antibodies. J Immunol. 1991;147:168–73.[PubMed][Google Scholar]
  • 467. Salvemini DRegulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci. 1997;53:576–82.[PubMed][Google Scholar]
  • 468. Sanan DA, Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer’s disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3. J Clin Invest. 1994;94:860–9.
  • 469. Sandi C, Loscertales M. Opposite effects on NCAM expression in the rat frontal cortex induced by acute vs. chronic corticosterone treatments. Brain Res. 1999;828:127–34.[PubMed]
  • 470. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336:1216–22.[PubMed]
  • 471. Sapolsky RM, Krey LC, McEwen BSProlonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5:1222–7.[Google Scholar]
  • 472. Sapolsky RM, Packan DR, Vale WWGlucocorticoid toxicity in the hippocampus: in vitro demonstration. Brain Res. 1988;453:367–71.[PubMed][Google Scholar]
  • 473. Sasaki A, Yamaguchi H, Ogawa A, Sugihara S, Nakazato YMicroglial activation in early stages of amyloid beta protein deposition. Acta Neuropathol (Berlin) 1997;94:316–22.[PubMed][Google Scholar]
  • 474. Satoh T, Nakamura S, Taga T, et al Induction of neuronal differentiation in PC12 cells by B-cell stimulatory factor 2/interleukin 6. Mol Cell Biol. 1988;8:3546–9.[Google Scholar]
  • 475. Sawada M, Kondo N, Suzumura A, Marunouchi TProduction of TNF-alpha by microglia and astrocytes in culture. Brain Res. 1989;491:394–7.[PubMed][Google Scholar]
  • 476. Schall TJ. The Chemokines. In: Thompson A, editor. The cytokine handbook. San Diego: Academic Press; 1994. pp. 419–60. [PubMed]
  • 477. Scheloske M, Haslinger A, Unger J, et al Expression of the IL-6 receptor complex (IL-6RC) in human rapid autopsy tissue. Neuroscience. 1999;25:1536. Abstract. [PubMed][Google Scholar]
  • 478. Schenk D, Barbour R, Dunn W, et al Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–7.[PubMed][Google Scholar]
  • 479. Schmaier AH, Dahl LD, Rozemuller AJ, et al. Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. J Clin Invest. 1993;92:2540–5.
  • 480. Schmidt LA, Fox NA, Goldberg MC, Smith CC, Schulkin JEffects of acute prednisone administration on memory, attention, and emotion in healthy human adults. Psychoneuroendocrinology. 1999;24:461–83.[PubMed][Google Scholar]
  • 481. Schmidt M, Pauels HG, Lugering N, Lugering A, Domschke W, Kucharzik TGlucocorticoids induce apoptosis in human monocytes: potential role of IL-1 beta. J Immunol. 1999;163:3484–90.[PubMed][Google Scholar]
  • 482. Schubert P, Ogata T, Rudolphi K, Marchini C, McRae A, Ferroni SSupport of homeostatic glial cell signaling: a novel therapeutic approach by propentofylline. Ann NY Acad Sci. 1997;826:337–47.[PubMed][Google Scholar]
  • 483. Schumann G, Huell M, Machein U, Hocke G, Fiebich BLIL-6 activates signal transducer and activator of transcription and mitogen-activated protein kinase signal transduction pathways and induces de novo protein synthesis in human neuronal cells. J Neurochem. 1999;73:2009–17.[PubMed][Google Scholar]
  • 484. Schwarzman AL, Gregori L, Vitek MP, et al Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci USA. 1994;91:8368–72.[Google Scholar]
  • 485. Scott SA, Johnson SA, Zarow C, Perlmutter LSInability to detect β-amyloid protein precursor mRNA in Alzheimer plaque-associated microglia. Exp Neurol. 1993;121:113–8.[PubMed][Google Scholar]
  • 486. Seab JP, Jagust WJ, Wong ST, Roos MS, Reed BR, Budinger TFQuantitative NMR measurements of hippocampal atrophy in Alzheimer’s disease. Magn Reson Med. 1988;8:200–8.[PubMed][Google Scholar]
  • 487. Selye H Stress in health, and disease. Boston: Butterworths; 1976. [PubMed][Google Scholar]
  • 488. Shaffer LM, Dority MD, Gupta–Bansal R, Frederickson RC, Younkin SG, Brunden KRAmyloid beta protein (Aβ) removal by neuroglial cells in culture. Neurobiol Aging. 1995;16:737–45.[PubMed][Google Scholar]
  • 489. Shago M, Flock G, Leung HC, et al Modulation of the retinoic acid and retinoid X receptor signaling pathways in P19 embryonal carcinoma cells by calreticulin. Exp Cell Res. 1997;230:50–60.[PubMed][Google Scholar]
  • 490. Shen Y, Halperin JA, Lee CMComplement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 1995;671:282–92.[PubMed][Google Scholar]
  • 491. Shen Y, Li R, McGeer EG, McGeer PLNeuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 1997;769:391–5.[PubMed][Google Scholar]
  • 492. Shen Y, Sullivan T, Lee CM, Meri S, Shiosaki K, Lin CWInduced expression of neuronal membrane attack complex and cell death by Alzheimer’s beta-amyloid peptide. Brain Res. 1998;796:187–97.[PubMed][Google Scholar]
  • 493. Shen Y, Yang L-B, Rogers JComplement defense protein CD59 is deficient in the Alzheimer’s brain. Neuroscience. 1999;25:1102. Abstract. [PubMed][Google Scholar]
  • 494. Sheng JG, Boop FA, Mrak RE, Griffin WSIncreased neuronal beta-amyloid precursor protein expression in human temporal lobe epilepsy: association with IL-1 alpha immunoreactivity. J Neurochem. 1994;63:1872–9.[Google Scholar]
  • 495. Sheng JG, Ito K, Skinner RD, et al In vivo and in vitro evidence supporting a role for the inflammatory cytokine IL-1 as a driving force in Alzheimer pathogenesis. Neurobiol Aging. 1996;17:761–6.[Google Scholar]
  • 496. Sheng JG, Mrak RE, Griffin WSS100 beta protein expression in Alzheimer disease: potential role in the pathogenesis of neuritic plaques. J Neurosci Res. 1994;39:398–404.[PubMed][Google Scholar]
  • 497. Sheng JG, Mrak RE, Rovnaghi CR, Kozlowska E, Van Eldik LJ, Griffin WSHuman brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer’s disease. Neurobiol Aging. 1996;17:359–63.[PubMed][Google Scholar]
  • 498. Shigematsu K, McGeer PL, Walker DG, Ishii T, McGeer EGReactive microglia/macrophages phagocytose amyloid precursor protein produced by neurons following neural damage. J Neurosci Res. 1992;31:443–53.[PubMed][Google Scholar]
  • 499. Shirahama T, Miura K, Ju ST, Kisilevsky R, Gruys E, Cohen ASAmyloid enhancing factor-loaded macrophages in amyloid fibril formation. Lab Invest. 1990;62:61–8.[PubMed][Google Scholar]
  • 500. Shrikant P, Weber E, Jilling T, Benveniste EN. Intercellular adhesion molecule-1 gene expression by glial cells. Differential mechanisms of inhibition by IL-10 and IL-6. J Immunol. 1995;155:1489–1501.[PubMed]
  • 501. Si Q, Nakamura Y, Ogata T, Kataoka K, Schubert PDifferential regulation of microglial activation by propentofylline via cAMP signaling. Brain Res. 1998;812:97–104.[PubMed][Google Scholar]
  • 502. Slotkin TA, Wang XF, Symonds HS, Seidler FJExpression of mRNAs coding for the transforming growth factor-beta receptors in brain regions of euthyroid and hypothyroid neonatal rats and in adult brain. Dev Brain Res. 1997;99:61–5.[PubMed][Google Scholar]
  • 503. Small GW, La Rue A, Komo S, Kaplan A, Mandelkern MAPredictors of cognitive change in middle-aged and older adults with memory loss. Am J Psychiatry. 1995;152:1757–64.[PubMed][Google Scholar]
  • 504. Small GW, Mazziotta JC, Collins MT, et al Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942–7.[PubMed][Google Scholar]
  • 505. Smith–Swintosky VL, Pettigrew LC, Craddock SD, Culwell AR, Rydel RE, Mattson MPSecreted forms of beta-amyloid precursor protein protect against ischemic brain injury. J Neurochem. 1994;63:781–4.[PubMed][Google Scholar]
  • 506. Smith MA, Richey HP, Sayre LM, Beckman JS, Perry GWidespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci. 1997;17:2653–7.[Google Scholar]
  • 507. Smith RP, Higuchi DA, Broze GJJPlatelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. Science. 1990;248:1126–8.[PubMed][Google Scholar]
  • 508. Snell JC, Chernyshev O, Gilbert DL, Colton CAPolyribonucleotides induce nitric oxide production by human monocyte-derived macrophages. J Leukoc Biol. 1997;62:369–73.[PubMed][Google Scholar]
  • 509. Snow AD, Mar H, Nochlin D, et al The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer’s disease. Am J Pathol. 1988;133:456–63.[Google Scholar]
  • 510. Somers W, Stahl M, Seehra JS. 1. 9 A crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. EMBO J. 1997;16:989–97.
  • 511. Sottrup–Jensen LAlpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem. 1989;264:11539–42.[PubMed][Google Scholar]
  • 512. Sparks DLCoronary artery disease, hypertension, ApoE, and cholesterol: a link to Alzheimer’s disease? Ann NY Acad Sci. 1997;826:128–46.[PubMed][Google Scholar]
  • 513. Spiegel K, Emmerling MR, Barnum SR Inflammatory mechanisms and management of neurodegeneration. Totowa, NJ: Humana Press; 1999. Acute phase proteins: strategies for inhibition of complement activation in the treatment of neurodegenerative disorders; pp. 129–76. [PubMed][Google Scholar]
  • 514. Stalder AK, Carson MJ, Pagenstecher A, et al Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of TNF. Am J Pathol. 1998;153:767–83.[Google Scholar]
  • 515. Stalder M, Phinney A, Probst A, Sommer B, Staufenbiel M, Jucker MAssociation of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol. 1999;154:1673–84.[Google Scholar]
  • 516. Stein BA, Sapolsky RMChemical adrenalectomy reduces hippocampal damage induced by kainic acid. Brain Res. 1988;473:175–80.[PubMed][Google Scholar]
  • 517. Steinman LSome misconceptions about understanding autoimmunity through experiments with knockouts. J Exp Med. 1997;185:2039–41.[Google Scholar]
  • 518. Sterneck E, Kaplan DR, Johnson PFIL-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J Neurochem. 1996;67:1365–74.[PubMed][Google Scholar]
  • 519. Stewart WF, Kawas C, Corrada M, Metter EJRisk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997;48:626–32.[PubMed][Google Scholar]
  • 520. Strauss S, Bauer J, Ganter U, Jonas U, Berger M, Volk BDetection of IL-6 and alpha 2-macroglobulin immunoreactivity in cortex and hippocampus of Alzheimer’s disease patients. Lab Invest. 1992;66:223–30.[PubMed][Google Scholar]
  • 521. Streit WJ, Sparks DLActivation of microglia in the brains of humans with heart disease and hypercholesterolemic rabbits. J Mol Med. 1997;75:130–8.[PubMed][Google Scholar]
  • 522. Streit WJ, Walter SA, Pennell NAReactive microgliosis. Prog Neurobiol. 1999;57:563–81.[PubMed][Google Scholar]
  • 523. Streiter RM, Polverini PJ, Kunkel SL, et al The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem. 1995;270:27348–57.[PubMed][Google Scholar]
  • 524. Strittmatter WJ, Weisgraber KH, Huang DY, et al Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90:8098–8102.[Google Scholar]
  • 525. Strohmeyer R, Shen Y, Rogers JDetection of complement alternative pathway mRNA and proteins in Alzheimer’s disease brain. Mol Brain Res. In press. [[PubMed]
  • 526. Stubner S, Schon T, Padberg F, et al IL-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130. Neurosci Lett. 1999;259:145–8.[PubMed][Google Scholar]
  • 527. Styren SD, Civin WH, Rogers JMolecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer’s disease brain. Exp Neurol. 1990;110:93–104.[PubMed][Google Scholar]
  • 528. Su JH, Deng G, Cotman CWNeuronal DNA damage precedes tangle formation and is associated with up-regulation of nitrotyrosine in Alzheimer’s disease brain. Brain Res. 1997;774:193–9.[PubMed][Google Scholar]
  • 529. Sullivan PG, Bruce–Keller AJ, Rabchevsky AG, et al Exacerbation of damage and altered NF-kappaB activation in mice lacking TNF receptors after traumatic brain injury. J Neurosci. 1999;19:6248–56.[Google Scholar]
  • 530. Sundsmo JS, Fair DSRelationship among the complement, kinin, coagulation, and fibrinolytic systems in the inflammatory reaction. Clin Physiol Biochem. 1983;1:225–84.[PubMed][Google Scholar]
  • 531. Suo Z, Tan J, Placzek A, Crawford F, Fang C, Mullan MAlzheimer’s beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res. 1998;807:110–7.[PubMed][Google Scholar]
  • 532. Suzuki S, Tanaka K, Nagata E, Ito D, Dembo T, Fukuuchi YCerebral neurons express IL-6 after transient forebrain ischemia in gerbils. Neurosci Lett. 1999;262:117–20.[PubMed][Google Scholar]
  • 533. Swanwick GR, Kirby M, Bruce I, et al Hypothalamic-pituitary-adrenal axis dysfunction in Alzheimer’s disease: lack of association between longitudinal and cross-sectional findings. Am J Psychiatry. 1998;155:286–9.[PubMed][Google Scholar]
  • 534. Taga TGp130, a shared signal transducing receptor component for hematopoietic and neuropoietic cytokines. J Neurochem. 1996;67:1–10.[PubMed][Google Scholar]
  • 535. Takeda A, Yasuda T, Miyata T, et al Advanced glycation end products co-localized with astrocytes and microglial cells in Alzheimer’s disease brain. Acta Neuropathol (Berlin) 1998;95:555–8.[PubMed][Google Scholar]
  • 536. Tamatani M, Che YH, Matsuzaki H, et al TNF induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J Biol Chem. 1999;274:8531–8.[PubMed][Google Scholar]
  • 537. Tanaka J, Fujita H, Matsuda S, Toku K, Sakanaka M, Maeda NGlucocorticoid- and mineralocorticoid receptors in microglial cells: the two receptors mediate differential effects of corticosteroids. Glia. 1997;20:23–37.[PubMed][Google Scholar]
  • 538. Tarkowski E, Blennow K, Wallin A, Tarkowski AIntracerebral production of TNF-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol. 1999;19:223–30.[PubMed][Google Scholar]
  • 539. Tchelingerian JL, Vignais L, Jacque CTNF alpha gene expression is induced in neurones after a hippocampal lesion. Neuroreport. 1994;5:585–8.[PubMed][Google Scholar]
  • 540. Teipel SJ, Hampel H, Alexander GE, et al Dissociation between corpus callosum atrophy and white matter pathology in Alzheimer’s disease. Neurology. 1998;51:1381–5.[PubMed][Google Scholar]
  • 541. Tennent GA, Lovat LB, Pepys MBSerum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA. 1995;92:4299–4303.[Google Scholar]
  • 542. Terai K, Walker DG, McGeer EG, McGeer PLNeurons express proteins of the classical complement pathway in Alzheimer disease. Brain Res. 1997;769:385–90.[PubMed][Google Scholar]
  • 543. Tocco G, Freire–Moar J, Schreiber SS, Sakhi SH, Aisen PS, Pasinetti GMMaturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer’s disease. Exp Neurol. 1997;144:339–49.[PubMed][Google Scholar]
  • 544. Tooyama I, Kawamata T, Akiyama H, Moestrup SK, Gliemann J, McGeer PLImmunohistochemical study of alpha 2 macroglobulin receptor in Alzheimer and control postmortem human brain. Mol Chem Neuropathol. 1993;18:153–60.[PubMed][Google Scholar]
  • 545. Trinder PK, Faust D, Petry F, Loos MModulation of mRNA expression and secretion of C1q in mouse macrophages by anti-inflammatory drugs and cAMP: evidence for the partial involvement of a pathway that includes cyclooxygenase, prostaglandin E2 and adenylate cyclase. Immunology. 1995;84:638–44.[Google Scholar]
  • 546. Ulvestad E, Williams K, Bjerkvig R, Tiekotter K, Antel J, Matre RHuman microglial cells have phenotypic and functional characteristics in common with both macrophages and dendritic antigen-presenting cells. J Leukoc Biol. 1994;56:732–40.[PubMed][Google Scholar]
  • 547. Unlap T, Jope RSDiurnal variation in kainate-induced AP-1 activation in rat brain: influence of glucocorticoids. Mol Brain Res. 1995;28:193–200.[PubMed][Google Scholar]
  • 548. Unlap T, Jope RSInhibition of NFkB DNA binding activity by glucocorticoids in rat brain. Neurosci Lett. 1995;198:41–4.[PubMed][Google Scholar]
  • 549. Unsicker K, Flanders KC, Cissel DS, Lafyatis R, Sporn MBTransforming growth factor beta isoforms in the adult rat central and peripheral nervous system. Neuroscience. 1991;44:613–25.[PubMed][Google Scholar]
  • 550. Uz T, Dwivedi Y, Savani PD, Impagnatiello F, Pandey G, Manev HGlucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain. J Neurochem. 1999;73:693–9.[PubMed][Google Scholar]
  • 551. Vakeva A, Laurila P, Meri SLoss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest. 1992;67:608–16.[PubMed][Google Scholar]
  • 552. Vallieres L, Rivest SRegulation of the genes encoding IL-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine IL-1beta. J Neurochem. 1997;69:1668–83.[PubMed][Google Scholar]
  • 553. van der Laan LJ, Ruuls SR, Weber KS, Lodder IJ, Dopp EA, Dijkstra CDMacrophage phagocytosis of myelin in vitro determined by flow cytometry: phagocytosis is mediated by CR3 and induces production of TNF-alpha and nitric oxide. J Neuroimmunol. 1996;70:145–52.[PubMed][Google Scholar]
  • 554. van der Wal EA, Gomez–Pinilla F, Cotman CWTransforming growth factor-beta 1 is in plaques in Alzheimer and Down pathologies. Neuroreport. 1993;4:69–72.[PubMed][Google Scholar]
  • 555. Van Eldik LJ, Griffin WSS100 beta expression in Alzheimer’s disease: relation to neuropathology in brain regions. Biochim Biophys Acta. 1994;1223:398–403.[PubMed][Google Scholar]
  • 556. Van Muiswinkel FL, DeGroot C, Rozemuller-Kwakkel J, Eikelenboom P Alzheimer’s disease and related disorders. London: John Wiley & Sons; 1999. Enhanced expression of microglial NADPH-oxidase (p22-phox) in Alzheimer’s disease; pp. 451–6. [PubMed][Google Scholar]
  • 557. Van Muiswinkel FL, Raupp SF, de Vos NM, et al The amino-terminus of the amyloid-beta protein is critical for the cellular binding and consequent activation of the respiratory burst of human macrophages. J Neuroimmunol. 1999;96:121–30.[PubMed][Google Scholar]
  • 558. Van Muiswinkel FL, Veerhuis R, Eikelenboom PAmyloid beta protein primes cultured rat microglial cells for an enhanced phorbol 12-myristate 13-acetate-induced respiratory burst activity. J Neurochem. 1996;66:2468–76.[PubMed][Google Scholar]
  • 559. Van Nostrand WE, Wagner SL, Suzuki M, et al Protease nexin-II, a potent antichymotrypsin, shows identity to amyloid beta-protein precursor. Nature. 1989;341:546–9.[PubMed][Google Scholar]
  • 560. Van Wagoner NJ, Oh JW, Repovic P, Benveniste ENIL-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci. 1999;19:5236–44.[Google Scholar]
  • 561. Vandenabeele P, Fiers WIs amyloidogenesis during Alzheimer’s disease due to an IL-1/IL-6 mediated ‘acute phase’ response in the brain. Immunol Today. 1991;12:217–9.[PubMed][Google Scholar]
  • 562. Vane JR, Bakhle YS, Botting RMCyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998;38:97–120.[PubMed][Google Scholar]
  • 563. Veerhuis R, Janssen CJA, De Groot FI, Van Muiswinkel FL, Hack P, Eikelenboom PCytokines associated with amyloid plaques in Alzheimer’s disease brains stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp Neurol. 1999;160:289–99.[PubMed][Google Scholar]
  • 564. Veerhuis R, Janssen I, Hoozemans JJ, De Groot CJ, Hack CE, Eikelenboom PComplement C1-inhibitor expression in Alzheimer’s disease. Acta Neuropathol. 1998;96:287–96.[PubMed][Google Scholar]
  • 565. Velazquez P, Cribbs DH, Poulos TL, Tenner AJAspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer’s disease pathogenesis. Nat Med. 1997;3:77–9.[PubMed][Google Scholar]
  • 566. Vergeli M, Mazzanti B, Ballerini C, Gran B, Amaducci L, Massacesi LTransforming growth factor-beta 1 inhibits the proliferation of rat astrocytes induced by serum and growth factors. J Neurosci Res. 1995;40:127–33.[PubMed][Google Scholar]
  • 567. Vijayan VK, Cotman CWHydrocortisone administration alters glial reaction to entorhinal lesion in the rat dentate gyrus. Exp Neurol. 1987;96:307–20.[PubMed][Google Scholar]
  • 568. Vitek MP, Snell J, Dawson H, Colton CAModulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem Biophys Res Commun. 1997;240:391–4.[PubMed][Google Scholar]
  • 569. Wagner SL, Geddes JW, Cotman CW, et al Protease nexin-1, an antithrombin with neurite outgrowth activity, is reduced in Alzheimer disease. Proc Natl Acad Sci USA. 1989;86:8284–8.[Google Scholar]
  • 570. Wahl SM, Allen JB, McCartney–Francis N, et al Macrophage- and astrocyte-derived transforming growth factor beta as a mediator of central nervous system dysfunction in acquired immune deficiency syndrome. J Exp Med. 1991;173:981–91.[Google Scholar]
  • 571. Walker DGExpression and regulation of complement C1q by human THP-1-derived macrophages. Mol Chem Neuropathol. 1998;34:197–218.[PubMed][Google Scholar]
  • 572. Walker DG, Kim SU, McGeer PLComplement and cytokine gene expression in cultured microglia derived from postmortem human brains. J Neurosci Res. 1995;40:478–93.[PubMed][Google Scholar]
  • 573. Walker DG, Kim SU, McGeer PLExpression of complement C4 and C9 genes by human astrocytes. Brain Res. 1998;809:31–8.[PubMed][Google Scholar]
  • 574. Walker DG, McGeer PLComplement gene expression in human brains: comparison between normal and Alzheimer Disease cases. Mol Brain Res. 1992;14:109–16.[PubMed][Google Scholar]
  • 575. Walker DG, Yasuhara O, Patston PA, McGeer EG, McGeer PLComplement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res. 1995;675:75–82.[PubMed][Google Scholar]
  • 576. Wang YQ, Sizeland A, Wang XF, Sassoon DRestricted expression of type-II TGF beta receptor in murine embryonic development suggests a central role in tissue modeling and CNS patterning. Mech Dev. 1995;52:275–89.[PubMed][Google Scholar]
  • 577. Ward LD, Howlett GJ, Discolo G, et al High affinity IL-6 receptor is a hexameric complex consisting of two molecules each of IL-6, IL-6 receptor, and gp- 130. J Biol Chem. 1994;269:23286–9.[PubMed][Google Scholar]
  • 578. Watanabe D, Yoshimura R, Khalil M, et al Characteristic localization of gp130 (the signal-transducing receptor component used in common for IL-6/IL-11/CNTF/LIF/OSM) in the rat brain. Eur J Neurosci. 1996;8:1630–40.[PubMed][Google Scholar]
  • 579. Watson MD, Roher AE, Kim KS, Spiegel K, Emmerling MRComplement interactions with amyloid-β 1–42: a nidus for inflammation in AD brains. Amyloid. 1997;4:147–56.[PubMed][Google Scholar]
  • 580. Wavrant–DeVrieze F, Rudrasingham V, Lambert JC, et al No association between the alpha-2 macroglobulin I1000V polymorphism and Alzheimer’s disease. Neurosci Lett. 1999;262:137–9.[PubMed][Google Scholar]
  • 581. Webb DJ, Atkins TL, Crookston KP, Burmester JK, Qian SW, Gonias SL. Transforming growth factor beta isoform 2-specific high affinity binding to native alpha 2-macroglobulin. Chimeras identify a sequence that determines affinity for native but not activated alpha 2-macroglobulin. J Biol Chem. 1994;269:30402–6.[PubMed]
  • 582. Webster S, Bradt B, Rogers J, Cooper NAggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J Neurochem. 1997;69:388–98.[PubMed][Google Scholar]
  • 583. Webster S, Glabe C, Rogers JMultivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem Biophys Res Commun. 1995;217:869–75.[PubMed][Google Scholar]
  • 584. Webster S, Lue LF, Brachova L, et al Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease. Neurobiol Aging. 1997;18:415–421.[PubMed][Google Scholar]
  • 585. Webster S, O’Barr S, Rogers JEnhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q. J Neurosci Res. 1994;39:448–56.[PubMed][Google Scholar]
  • 586. Webster S, Park M, Fonseca MI, Tenner AJ Structural and functional evidence for a microglial C1q receptor that enhances phagocytosis. J Leukoc Biol. 2000;67:109–16.[PubMed][Google Scholar]
  • 587. Webster S, Rogers JRelative efficacies of amyloid beta peptide (Aβ) binding proteins in A beta aggregation. J Neurosci Res. 1996;46:58–66.[PubMed][Google Scholar]
  • 588. Webster S, Tenner AJ, Poulos TL, Cribbs DThe mouse C1q A chain sequence alters beta-amyloid induced complement activation. Neurobiol Aging. 1999;20:297–304.[PubMed][Google Scholar]
  • 589. Webster S, Yang AJ, Margol L, Garzon–Rodaquez W, Glabe C, Tenner AJComplement component C1q modulates the phagocytosis of Aβ by rat microglia. Exp Neurol. 2000;161:127–38.[PubMed][Google Scholar]
  • 590. Weiner MF, Vobach S, Olsson K, Svetlik D, Risser RCCortisol secretion and Alzheimer’s disease progression. Biol Psychiatry. 1997;42:1030–8.[PubMed][Google Scholar]
  • 591. Wekerle H, Linnington C, Lassmann H, Meyermann RCellular immune reactivity within the CNS. Trends Neurosci. 1986;9:271–7.[PubMed][Google Scholar]
  • 592. Wekerle H, Sun D, Oropeza–Wekerle RL, Meyermann RImmune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. J Exp Biol. 1987;132:43–57.[PubMed][Google Scholar]
  • 593. Weng Y, Siciliano SJ, Walburger KE, et al Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 1998;273:18288–91.[PubMed][Google Scholar]
  • 594. Wenk GL, Hauss–Wegrzyniak B, Willard LB Research and perspectives in neurosciences: neuroimmune neurodegenerative and psychiatric disorders. Heidelberg: Springer-Verlag; 2000. Pathological and biochemical studies of chronic neuroinflammation may lead to therapies for Alzheimer’s Disease; pp. 73–7. [PubMed][Google Scholar]
  • 595. Wenk GL, Willard LBThe neural mechanisms underlying cholinergic cell death within the basal forebrain. Int J Dev Neurosci. 1998;16:729–35.[PubMed][Google Scholar]
  • 596. Willard LB, Hauss–Wegrzyniak B, Wenk GLPathological and biochemical consequences of acute and chronic neuroinflammation within the basal forebrain cholinergic system of rats. Neuroscience. 1999;88:193–200.[PubMed][Google Scholar]
  • 597. Williams SE, Kounnas MZ, Argraves KM, Argraves WS, Strickland DK. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein and the receptor-associated protein. An overview. Ann NY Acad Sci. 1994;737:1–13.[PubMed]
  • 598. Wisniewski HM, Wegiel J, Wang KC, Kujawa M, Lach BUltrastructural studies of the cells forming amyloid fibers in classical plaques. Can J Neurol Sci. 1989;16:535–42.[PubMed][Google Scholar]
  • 599. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione BAcceleration of Alzheimer’s fibril formation by apolipoprotein E in vitro. Am J Pathol. 1994;145:1030–5.[Google Scholar]
  • 600. Wolf BB, Lopes MB, VandenBerg SR, Gonias SLCharacterization and immunohistochemical localization of alpha 2-macroglobulin receptor (low-density lipoprotein receptor-related protein) in human brain. Am J Pathol. 1992;141:37–42.[Google Scholar]
  • 601. Wolkowitz OM, Reus VI, Canick J, Levin B, Lupien SGlucocorticoid medication, memory and steroid psychosis in medical illness. Ann NY Acad Sci. 1997;823:81–96.[PubMed][Google Scholar]
  • 602. Wood JA, Wood PL, Ryan R, et al Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1 beta or IL-1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res. 1993;629:245–52.[PubMed][Google Scholar]
  • 603. Wood JG, Zinsmeister PTyrosine phosphorylation systems in Alzheimer’s disease pathology. Neurosci Lett. 1991;121:12–6.[PubMed][Google Scholar]
  • 604. Wood SJ, Chan W, Wetzel RSeeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry. 1996;35:12623–8.[PubMed][Google Scholar]
  • 605. Woods AG, Poulsen FR, Gall CMDexamethasone selectively suppresses microglial trophic responses to hippocampal deafferentation. Neuroscience. 1999;91:1277–89.[PubMed][Google Scholar]
  • 606. Wu MF, Chang HL, Tseng JDehydroepiandrosterone induces the transforming growth factor-beta production by murine macrophages. Int J Tissue React. 1997;19:141–8.[PubMed][Google Scholar]
  • 607. Wyss–Coray T, Feng L, Masliah E, et al Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am J Pathol. 1995;147:53–67.[Google Scholar]
  • 608. Wyss-Coray T, Lacombe P, Lin C, Sanan DA, Mucke L, Masliah EAlzheimer’s disease-like cerebrovascular pathology in transforming growth factor-β1 transgenic mice and functional metabolic correlates. Ann NY Acad Sci. In press. [[PubMed]
  • 609. Wyss–Coray T, Lacombe P, Von Euw D, et al TGF-β1 modulates brain amyloid deposition and induces Alzheimer’s disease like microvascular abnormalities in transgenic mice. Neurosci. 1999;25:22. Abstract. [PubMed][Google Scholar]
  • 610. Wyss–Coray T, Lin C, Sanan DA, Mucke L, Masliah EChronic overproduction of TGF-β1 in astrocytes promotes Alzheimer’s disease-like microvascular degeneration in transgenic mice. Am J Pathol. 2000;156:139–50.[Google Scholar]
  • 611. Wyss–Coray T, Masliah E, et al Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer’s disease. Nature. 1997;389:603–6.[PubMed][Google Scholar]
  • 612. Xia MQ, Hyman BChemokines/chemokine receptors in the central nervous system and Alzheimer’s disease. J Neurovirol. 1999;5:32–41.[PubMed][Google Scholar]
  • 613. Xia MQ, Qin SX, McNamara M, Mackay CR, Hyman BIL-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer’s disease. Am J Pathol. 1997;150:1267–74.[Google Scholar]
  • 614. Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BTImmunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am J Pathol. 1998;153:31–7.[Google Scholar]
  • 615. Yagisawa M, Yuo A, Yonemaru M, et al Superoxide release and NADPH oxidase components in mature human phagocytes: correlation between functional capacity and amount of functional proteins. Biochem Biophys Res Commun. 1996;228:510–6.[PubMed][Google Scholar]
  • 616. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PFExpression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron. 1993;11:371–86.[PubMed][Google Scholar]
  • 617. Yamamoto K, Arakawa T, Ueda N, Yamamoto STranscriptional roles of nuclear factor kappa B and nuclear factor-IL-6 in the TNF alpha-dependent induction of cyclooxygenase-2 in MC3T3–E1 cells. J Biol Chem. 1995;270:31315–20.[PubMed][Google Scholar]
  • 618. Yamamoto K, Miyoshi T, Yae T, et al The survival of rat cerebral cortical neurons in the presence of trophic APP peptides. J Neurobiol. 1994;25:585–94.[PubMed][Google Scholar]
  • 619. Yan SD, Zhu H, Fu J, et al Amyloid-beta peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc Natl Acad Sci USA. 1997;94:5296–5301.[Google Scholar]
  • 620. Yan SD, Chen X, Fu J, et al RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature. 1996;382:685–91.[PubMed][Google Scholar]
  • 621. Yan SD, Yan SF, Chen X, et al Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid beta-peptide. Nat Med. 1995;1:693–9.[PubMed][Google Scholar]
  • 622. Yang Y, Quitschke WW, Brewer GJUpregulation of amyloid precursor protein gene promoter in rat primary hippocampal neurons by phorbol ester, IL-1 and retinoic acid, but not by reactive oxygen species. Mol Brain Res. 1998;60:40–9.[PubMed][Google Scholar]
  • 623. Yao J, Harvath L, Gilbert DL, Colton CAChemotaxis by a CNS macrophage, the microglia. J Neurosci Res. 1990;27:36–42.[PubMed][Google Scholar]
  • 624. Yao J, Keri JE, Taffs RE, Colton CACharacterization of IL-1 production by microglia in culture. Brain Res. 1992;591:88–93.[PubMed][Google Scholar]
  • 625. Yasojima K, McGeer EG, McGeer PLComplement regulator C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer’s disease. Brain Res. 1999;833:297–301.[PubMed][Google Scholar]
  • 626. Yasojima K, Schwab C, McGeer EG, McGeer PLUp-regulated production and activation of the complement system in Alzheimer’s disease brain. Am J Pathol. 1999;154:927–36.[Google Scholar]
  • 627. Yasuhara O, Walker DG, McGeer PLHageman factor and its binding sites are present in senile plaques of Alzheimer’s disease. Brain Res. 1994;654:234–40.[PubMed][Google Scholar]
  • 628. Yasukawa K, Saito T, Fukunaga T, et al Purification and characterization of soluble human IL-6 receptor expressed in CHO cells. J Biochem (Tokyo) 1990;108:673–6.[PubMed][Google Scholar]
  • 629. Yermakova A, Rollins J, Callahan LM, Rogers J, O’Banion MKCyclooxygenase-1 in human Alzheimer’s and control brain:quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol. 1999;58:1135–46.[PubMed][Google Scholar]
  • 630. Yoshida T, Imai T, Kakizaki M, Nishimura M, Takagi H, Yoshie OIdentification of single C motif-1/lymphotactin receptor XCR1. J Biol Chem. 1998;273:16551–4.[PubMed][Google Scholar]
  • 631. Zarow C, Schlueter KE, Zhang QIL-6 mRNA is elevated in Alzheimer Disease Brain. Neurosci. 1996;22:214. Abstract. [PubMed][Google Scholar]
  • 632. Zhang JG, Owczarek CM, Ward LD, et al Evidence for the formation of a heterotrimeric complex of leukaemia inhibitory factor with its receptor subunits in solution. Biochem J. 1997;325:693–700.[Google Scholar]
  • 633. Zhong J, Dietzel ID, Wahle P, Kopf M, Heumann RSensory impairments and delayed regeneration of sensory axons in IL-6-deficient mice. J Neurosci. 1999;19:4305–13.[Google Scholar]
  • 634. Zlokovic BV, Martel CL, Mackic JB, et al Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer’s amyloid beta. Biochem Biophys Res Commun. 1994;205:1431–7.[PubMed][Google Scholar]
  • 635. Zlokovic BV, Martel CL, Matsubara E, et al Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA. 1996;93:4229–34.[Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.